

Potential Modes of Interaction of 9-Aminomethyl-9,10-dihydroanthracene (AMDA) Derivatives with the 5-HT_{2A} Receptor: A Ligand Structure-Affinity Relationship, Receptor Mutagenesis and Receptor Modeling Investigation

Scott P. Runyon,^{†,‡} Philip D. Mosier,[‡] Bryan L. Roth,[§] Richard A. Glennon,[‡] and Richard B. Westkaemper^{*,‡}

Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599

Received June 24, 2008

The effects of 3-position substitution of 9-aminomethyl-9,10-dihydroanthracene (AMDA) on 5-HT_{2A} receptor affinity were determined and compared to a parallel series of DOB-like 1-(2,5-dimethoxyphenyl)-2-aminopropanes substituted at the 4-position. The results were interpreted within the context of 5-HT_{2A} receptor models that suggest that members of the DOB-like series can bind to the receptor in two distinct modes that correlate with the compounds' functional activity. Automated ligand docking and molecular dynamics suggest that all of the AMDA derivatives, the parent of which is a 5-HT_{2A} antagonist, bind in a fashion analogous to that for the sterically demanding antagonist DOB-like compounds. The failure of the F340^{6,52}L mutation to adversely affect the affinity of AMDA and the 3-bromo derivative is consistent with the proposed modes of orientation. Evaluation of ligand–receptor complex models suggest that a valine/threonine exchange between the 5-HT_{2A} and D₂ receptors may be the origin of selectivity for AMDA and two substituted derivatives.

Introduction

Serotonin has been implicated in a large number of processes including the regulation of sleep, appetite, mood, aggression, perception, memory, and anxiety.¹ Thirteen distinct 5-HT G protein-coupled receptors (GPCRs⁴) have evolved that are divided into six main families.² Not surprisingly, alterations of 5-HT receptor activity have been shown to occur in many psychiatric diseases including anxiety, depression, eating disorders, schizophrenia, personality disorders, and many drug-induced psychotic states.² Additionally, a number of effective psychopharmacologic agents for diseases as diverse as depression, schizophrenia, and anxiety have been developed that either specifically alter brain levels of serotonin or bind to 5-HT receptor subtypes.^{1,3} Over the past few years, all of the 5-HT receptor subtypes have been cloned and sequenced.^{3,4} Among the first to be studied were the 5-HT_{2A} and 5-HT_{2C} receptors, and a significant body of reliable information has been accumulated regarding these 5-HT₂ receptors. Nevertheless, it is still not known with certainty how serotonergic agents (or, for that matter, how the endogenous ligand 5-HT itself) interact at 5-HT receptors. Crucial to an understanding of how serotonergic agents act, whether agonists, partial agonists, or antagonists, is some understanding of this drug–receptor interaction. A novel

class of high-affinity 5-HT₂ agents^{5–9} has been described, the parent structure of which (**1a**, 9-aminomethyl-9,10-dihydroanthracene, AMDA) is a 5-HT₂ selective⁶ antagonist⁸ that appears to bind with the 5-HT_{2A} receptor in a fashion distinct from classical tricyclic agents.^{6,9} As an anthracene derivative, AMDA is a fairly conformationally restrained molecule. Its 9-aminomethyl group is preferentially oriented in a pseudoaxial¹⁰ conformation, and its tricyclic ring system exhibits a fold angle of about 147°. Because AMDA (**1a**) shares a phenylethylamine skeleton with phenylethylamine agonists such as DOB (**2b**), potential binding mode relationships between AMDA and phenylethylamines were evaluated by exploring the effects of substitution at the 3-position of AMDA and the effects of the structurally analogous 4-position substitution of DOB-like phenylethylamine derivatives upon the binding affinity. Possible modes of binding of AMDA analogues and phenylethylamines were identified using 5-HT_{2A} receptor models constructed from the crystal structure of bovine rhodopsin. These studies have allowed us to formulate some useful generalizations about binding modes of agonists versus antagonists as well as to identify potential explanations for the observed receptor selectivity in the AMDA series.

Results and Discussion

Chemistry. The structures of the target compounds **1a–h**, **3a**, **3b**, **3d**, **4a**, **4b**, and **4d** are shown in Table 1. Compound **1a** was prepared using a literature procedure.⁸ Compounds **2a–e** and **2g** have also been previously reported in the literature, and their syntheses are discussed elsewhere.^{11–13} Compounds **3a** and **4a** were obtained from commercial sources. Compound **4a** was purchased as the free base and subsequently converted to the HCl salt¹⁴ using ethereal HCl. Compound **3c** was prepared as previously described.¹⁵

The synthesis of compounds **1b–h** was not without difficulty. The initial plan was to convert 3-substituted anthrones to the desired aminomethanes in a straightforward fashion. This route proved unsuccessful due to the rapid isomerization of anthrone

* To whom correspondence should be addressed. Phone: (804)828-6449. Fax: (804)828-7625. E-mail: rbwestka@vcu.edu. Address: Department of Medicinal Chemistry, P.O. Box 980540, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298-0540.





[†] Current address: Organic and Medicinal Chemistry, Research Triangle Institute.

[‡] Department of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University.

[§] Department of Pharmacology, University of North Carolina School of Medicine.


^a Abbreviations: AMDA, 9-aminomethyl-9,10-dihydroanthracene; DOB, 2,5-dimethoxy-4-bromoamphetamine; DOI, 2,5-dimethoxy-4-iodoamphetamine; 5-HT, serotonin; LSD, lysergic acid diethylamide; GPCR, G protein-coupled receptor; 5-HT_{2A}, serotonin receptor subtype 2A; D₂, dopamine receptor subtype 2; SERT, serotonin transporter; NET, norepinephrine transporter; TM, transmembrane; PDB, Protein Data Bank.

Table 1. Effects of Aromatic Substitution on 5-HT_{2A} Receptor Affinity

			
1a-h	2a-e, g	3a-d	4a,b,d

R ₁	R ₂	compd	K _i , nM ^a	compd	K _i , nM ^b	compd	K _i , nM ^a	compd	K _i , nM ^a
−H	−H	1a	20	2a	5200	3a	16800	4a	4610
−Br	−H	1b	1.3	2b	41	3b	1770	4b	260
−(CH ₂) ₃ Ph	−H	1c	3.2	2c	10	3c	60 ^c		
−C ₆ H ₁₃	−H	1d	7.0	2d	2.5	3d	78	4d	200
−OCH ₃	−H	1e	7.5	2e	1200				
−O(CH ₂) ₄ CH ₃	−H	1f	23						
−OH	−H	1g	107	2g	> 50000				
−C ₆ H ₁₃	−OCH ₃	1h	43						

^a [³H]Ketanserin labeled cloned 5-HT_{2A} sites. Values represent the mean of computer-derived K_i estimates (using LIGAND) of quadruplicate determinations. Standard errors typically range between 15–25% of the K_i value. ^b [³H]Ketanserin-labeled 5-HT_{2A} sites. ^c [³H]Ketanserin-labeled 5-HT_{2A} sites.¹⁵


Scheme 1^a

^a Reagents and conditions: (a) (1) 2-amino-2-methyl-1-propanol, CH₂Cl₂; (2) SOCl₂, toluene. (b) *sec*-Butyllithium, THF –78 °C. (c) 5% HCl 10 h. (d) 10% Pd/Charcoal, HClO₄ (cat), 2-PrOH. (e) BH₃-THF. (f) PCC, CH₂Cl₂. (g) Trimethylsilyl cyanide, CH₂Cl₂. (h) LiAlH₄, THF. (i) Eaton's reagent, PPA, or methane sulfonic acid. (j) BBr₃, CH₂Cl₂.

to 9-anthrol under acidic and basic conditions. Under most nucleophilic conditions, anthrone was converted to the 9-alkyl anthracenes by dehydration of the intermediate 9-alkyl-9-hydroxy anthracene. Treatment of anthrone with the Tebbe reagent¹⁶ did, however, provide 9-methylene-9,10-dihydroanthracene in modest yields. It was expected that 9-methylene-9,10-dihydroanthracene could then be oxidized to the 9-amino-9,10-dihydroanthracene with BH₃ and Chloramine T. Unfortunately, we were unable to generate large enough quantities of the 9-methylene-9,10-dihydroanthracene for this route to prove practical. Our focus changed following a review of the synthetic strategy employed by the Nichols group.¹⁷ The synthetic utility of an oxazoline as an ortho lithiating agent provided the key intermediates essential to the synthesis of compounds **1d–h** (Scheme 1). 4-Substituted phenyloxazolines were used to provide compounds **1e** and **1f**. In these cases, it

was reasoned that strongly electron donating groups (methoxy and pentyloxy) in the para position would facilitate the Friedel–Crafts cyclodehydration reaction ((i) Scheme 1). Performing the cyclodehydration reaction of the aminoalcohol intermediates **20** with weakly electron donating substituents (R₂ = hexyl, phenylpropyl) could lead to a mixture of two regioisomers. Separation of the resulting 1- and 3-substituted isomers would prove difficult because the free bases of compounds **1a–h** are remarkably unstable. Exposure to air and/or aqueous conditions causes a rapid (30 min–1 h) degradation to unknown highly colored compounds. Thus, 3-substituted benzaldehydes were used to generate compounds **1e**, **1f**, and **1g**.

The general synthetic approach¹⁷ (Scheme 1) began with ortho lithiation of **16** using *sec*-butyl lithium. The appropriate benzaldehydes were then added to the lithium anion at 0 °C. The


Scheme 2^a

^a Reagents and conditions: (a) THF, 10 °C; (b) conc HCl, MeOH; (c) PPA, room temp; (d) SnCl₂, EtOH.

crude reaction mixtures were subjected to acidic hydrolysis giving rise to the lactones **17d,e,f,h** in moderate overall yield. The lactones were hydrogenated in 2-PrOH with a catalytic amount of HClO₄ to give the acids **18d,e,f,h** in good yields. The acids were then reduced with BH₃-THF and reoxidized with PCC to give the aldehydes **19d,e,f,h** in excellent yields. The aldehydes were converted to the appropriately substituted 2-amino-1-hydroxy-(2-benzylphenyl)ethanols **20d,e,f,h** using TMSCN with a catalytic amount of ZnI₂ followed by LiAlH₄ reduction in THF. The target compounds **1d–h** were then prepared through a cyclodehydration reaction using either PPA, Eaton's reagent, or methanesulfonic acid. Compound **1g** was prepared from the hydrobromide salt of compound **1e** with BBr₃ in CHCl₃.¹⁷

An alternate route was chosen for the synthesis of **1b** due to the presence of a bromine capable of undergoing lithium insertion (Scheme 1). The Grignard **5** reacted in a 1,4 manner with 4-bromophenyl nitrostyrene (Scheme 2) to provide **6** by the method of Ashwood et al.¹⁸ Deprotection of the alcohol **6** with HCl in methanol followed by the PPA mediated cyclodehydration provided **8** in very low yield. The poor yield of the cyclodehydration reaction can be attributed to the deactivating nature of the bromo substituent. However, this route provided **8** in a regiochemically unambiguous manner. SnCl₂ reduction of the nitro group in **8** was chosen to eliminate any potential halogen loss.¹⁹

Compound **14**, the precursor of **1c**, was prepared as shown in Scheme 3. Compound **10** was obtained by benzylic bromination (NBS in CCl₄) of 4-bromo-2-methylbenzonitrile, followed by Friedel–Crafts alkylation with benzene. Conversion of the cyano group **10** to the aldehyde was carried out in a stepwise manner using KOH in ethylene glycol,²⁰ followed by reduction of the acid with BH₃-THF and reoxidation to the aldehyde **13** with PCC in CH₂Cl₂. This method was found to be superior to DIBAL reduction of the nitrile due to difficulties encountered in the separation of the aldehyde from the starting materials even with the use of aldehyde conjugation reagents such as sodium hydrogen sulfite. A modified Suzuki coupling reaction was employed to introduce the phenylpropyl substituent using allylbenzene/9-BBN followed by PdCl₂(dppf) and NaOH in

Scheme 3^a

^a Reagents and conditions: (a) NBS, CCl₄; (b) AlCl₃, benzene; (c) KOH, ethylene glycol; (d) BH₃-THF; (e) PCC, CH₂Cl₂; (f) 1; allylbenzene, 9-BBN 2; PdCl₂(dppf), NaOH, THF.

THF.²¹ The synthesis of **1c** from **14** was identical to that previously described for **1d,e,f,h** (Scheme 1) by conversion of the aldehyde to the 2-amino-1-hydroxy-[2-benzyl-4-(3-*n*-phenylpropyl)phenyl]ethanol followed by cyclodehydration using Eaton's reagent.

4-Bromophenylethylamine (**3b**) was prepared by BH₃-THF reduction of 4-bromophenyl acetonitrile. 4-*n*-Hexylbenzoyl cyanide **26** was prepared as per the method of Olah et al.²² using SnCl₄ and TMSCN. The benzoyl cyanide was reduced to the target 4-*n*-hexylphenylethylamine (**3d**) using catalytic hydrogenation (10% Pd/C in acetic acid).²³ Friedel–Crafts alkylation of 2-bromo-2-(4-bromophenyl)acetonitrile with benzene²⁴ provided the diphenyl acetonitrile **27**, which was reduced with BH₃-THF complex to provide the target **4b**. Compound **4d** was prepared by the reaction of 4-*n*-hexylbenzoyl chloride with benzene and AlCl₃ to provide **28** (4-*n*-hexylphenyl)(phenyl)methanone. Trimethylsilyl cyanide was then employed in the preparation of the cyanohydrin **29** followed by reduction of the hydroxy group with NaBH₄ in TFA²⁵ to provide **30** (2-(4-*n*-hexylphenyl)-2-phenylacetonitrile). Reduction of the nitrile was then carried out using Raney nickel under a hydrogen atmosphere to provide **4d** in moderate yield.

Biological Evaluation/5-HT_{2A} Receptor Affinities. Radioligand binding data (5-HT_{2A} receptor affinities) were obtained for each of the target compounds (Table 1). The 5-HT_{2A} receptor can accommodate a wide range of substituents associated with the 3-position of AMDA (**1a–g**; Table 1). Affinities varied only about 80-fold (**1b**, K_i = 1.3 nM; **1g**, K_i = 107 nM) within the series. With the exception of the 3-hydroxy compound (**1g**, K_i = 107 nM), monosubstitution of AMDA (**1a**, K_i = 20 nM) either does not change (**1f**, K_i = 23 nM) or increases affinity to a maximum of 15-fold (**1b**, K_i = 1.3) regardless of steric bulk or electronic character of the substituent. The effects of 4-position substitution on the affinities of 1-(2,5-dimethoxy)-2-aminopropanes (DOX; **2a–e**) are qualitatively similar in that each of these, with the exception of the hydroxy substituent (**2g**, K_i > 50000 nM), retains or enhances affinity. However, in the DOX series, the range of affinity enhancement is much greater (**2d**, K_i = 2.5 nM; **2a**, K_i = 5200 nM) than for the AMDA series with a maximum range of about 2000-fold, excluding the 4-hydroxy compound (**2g**) that shows no measurable affinity. Consistent with these observations, the lipophilic character of the 4-position substituent of DOX has been shown to modulate affinity over a broad range.¹³ These results suggest that the AMDA and DOX series may interact differently with the 5-HT_{2A} receptor. The principal structural feature distinguishing

AMDA from other phenylethylamines is the presence of a second, fused aromatic group. Introduction of a second nonfused phenyl group to phenylethylamine, (i.e., 2,2-diphenylethylamine) slightly increases affinity (**3a**, $K_i = 16800$ nM; **4a**, $K_i = 4610$ nM). Introduction of 4-substituents can enhance the affinity of phenylethylamine by about 280-fold (**3a**, $K_i = 16800$ nM; **3c**, $K_i = 60$ nM; Table 1) and 2,2-diphenylethylamine by about 23-fold (**4a**, $K_i = 4610$ nM; **4d**, $K_i = 200$ nM). These increases in affinity (particularly with respect to the phenylethylamines) are greater than the increases seen in the AMDA series (**1a**, **1b**; 15-fold), suggesting that there are differences in the modes of receptor interaction. Thus, it appears that DOB-like compounds, AMDA derivatives, and ring-opened AMDA derivatives (i.e., **3** and **4**) behave differently with respect to their binding at the 5-HT_{2A} receptor. This is perhaps not surprising given the fact that DOB is an agonist,¹⁵ whereas AMDA is an antagonist.⁸ At the very least, even if the two series bind in a comparable fashion, they must interact preferentially with functionally and conformationally distinct forms of the receptor. An alternative possibility is that the binding sites of agonists and antagonists only share a common ammonium ion binding site with the remaining bulk of each type of agent occupying completely different domains within the receptor.

Receptor Complex Models. There are numerous examples of similar compounds binding quite differently to a common receptor as well as ligands with multiple binding modes at a single receptor.^{9,26} Analysis of early 5-HT_{2A} receptor models led us to consider two general areas of steric accessibility, as depicted in Figure 1: site 1 (TM3 flanked by TM4, TM5, and TM6) and site 2 (TM3 flanked by TM1, TM2, TM6, and TM7). The presence of two distinct binding sites for GPCRs has been noted in the literature.²⁷ Previously, consideration of ligand SAR and receptor mutagenesis data prompted us to provisionally consider site 1 the “agonist site” and site 2 the “antagonist site.”^{28–30} Similar suggestions have also been made for the 5-HT_{1A} receptor.³¹ Subsequently, the method used here to select “agonist-biased” and “antagonist-biased” receptor models from a population of conformationally distinct receptor models (described in detail in the Experimental Section) has identified site 1 as an agonist binding site and site 2 as an antagonist binding site. The selected models identified in this way are thus referred to in this work as the agonist and antagonist receptor models, respectively. The computational methodology used in this work was designed to mimic the current model of protein–ligand binding in which the ligand selects a particular receptor conformation from an ensemble of metastable states.³² Site 1 and site 2 overlap, and the shared region between these sites includes residues that are a part of helices TM3 (D155^{3,32} and S159^{3,36}) and TM6 (W336^{6,48} and F339^{6,51}).³³

Whenever receptor homology models are generated whose purpose is to model the interaction of an agonist with the receptor, the accuracy of these models is called into question (more so than for antagonist–interaction models) since, until very recently, only inactive or ground-state rhodopsin crystal structures were available as homology modeling templates. More precisely, the additional requirement of an agonist to activate or trigger the receptor is thought to involve large-scale movements of at least part of the secondary structure of the receptor, making the activated receptor’s conformation significantly different from the inactive state’s conformation. Currently, such large-scale changes in conformation are not routinely incorporated into homology models. Recent crystallographic evidence, however, suggests that the conformation of the activated form of bovine rhodopsin does *not* significantly change in the ligand




Figure 1. (A) Schematic representation of sterically accessible binding sites within the 5-HT_{2A} receptor provisionally considered to be the agonist site (site 1) and the antagonist site (site 2).^{28,29} (B) Connolly channel depicting site 1 and site 2 within the 5-HT_{2A} receptor model. The GOLD-generated docking mode for AMDA is also shown (CPK space-filling model) to highlight the complementarity between the shape of site 2 and the fold angle of the AMDA ring system. D155^{3,32} is shown for reference (ball-and-stick model).

binding region: Salom et al.³⁴ have obtained a crystal structure, at 4.15 Å resolution, of the deprotonated form of metarhodopsin II (Meta II), the fully activated state of rhodopsin. This structure is strikingly similar to the structure of ground-state rhodopsin in the transmembrane and extracellular loop regions, where ligand binding sites are located. The authors thus conclude that “rhodopsin is a good template for homology models of other GPCRs used in docking calculations of both agonists and antagonists because ground-state and photoactivated rhodopsin are structurally similar”.³⁴ Other studies have proposed that a cluster of residues on TM6 in site 1 form a molecular “toggle switch” that is responsible for the activation of rhodopsin-like GPCRs.³⁵ This work utilizes the ground-state conformation of bovine rhodopsin (A chain of 1U19; 2.2 Å resolution) as a homology modeling template. However, the conformations of the side chains (and the backbone to a lesser degree) are allowed to vary from that of the template rhodopsin structure.

Viewed from the perspective of the ligand, in the most general terms it is usually observed that structures of antagonists differ from the endogenous neurotransmitters and other agonists in that they either lack key functional groups or present molecular features in areas of space not occupied/utilized by any portion of the agonist (i.e., an “accessory site”), or both.³⁶ For example, while 5-methoxytryptamine is a serotonin agonist, tryptamine is a partial agonist (see the review by Glennon, Westkaemper,

and Bartyzel³⁷); also, it has been shown that 2-phenyltryptamines are high-affinity 5-HT_{2A} receptor antagonists.³⁸ Similarly, LSD is an agonist or partial agonist whereas 2-bromo LSD is an antagonist.³⁹ In the DOX series, compounds with small substituents at the 4-position are agonists and those with bulky substituents such as phenylpropyl are antagonists.^{13,15} In the latter case, the 2,5-dimethoxy groups of 1-(2,5-dimethoxy-4-(3-phenylpropyl)phenyl)-2-aminopropane (**2c**), functional groups characteristically required for agonist activity, are no longer required for binding and, in fact, the desmethoxy parent **3c** has comparable affinity to the 2,5-dimethoxy substituted derivative.^{13,15} A similar observation can be made for **2d** and **3d**. It has been hypothesized that phenylalkylamines with small 4-position substituents (e.g., **2a**, **2b**, **2e**) bind differently from those with bulky 4-position substituents (e.g., **2c**, **2d**). Models of complexes of the 5-HT_{2A} receptor and DOB support the notion that there may be limited bulk tolerance at the 4-position for some modes of binding. Bound within site 1, substituents at the 4-position of DOX project into the interfacial region between TM5 and TM6 (see Figure 2A for an example). Preliminary modeling studies have indicated that, whereas 4-methyl and 4-ethyl substituents appear to be tolerated in the DOB-like series, successively adding methylene units to the 4-position of 1-(2,5-dimethoxy-4-ethylphenyl)-2-aminopropane bound to the receptor actually causes a displacement of the aromatic ring (2.3 Å) from the initial site on minimization. The bound ligand **2d** is rapidly displaced from its initial site during dynamics simulations (100 ps, 300 K, range constraint NH-OD155, 1.3–2.6 Å, helix backbone constrained) whereas DOB (**2b**) is not. Another possible binding mode would place large 4-position substituents in site 2 (Figure 1). A 5-HT_{2A} receptor model with the phenylethylamine **3d** bound in site 2 did not show displacement of the aromatic ring, and the ligand remained in the binding site on dynamics simulation.

The effects of *N*-alkylation and *N*-benzylation appear to support the notion that DOB and AMDA interact with the receptors differently. In the case of both 5-methoxytryptamine and DOB, successive *N*-methylation decreased affinity but *N*-benzyl DOB and *N*-benzyl-5-methoxytryptamine have slightly higher affinities (2- to 6-fold) than their parents.⁴⁰ In the AMDA series, successive *N*-methylation also decreased affinity but, unlike the DOB and 5-methoxytryptamine series, *N*-benzylation decreased affinity (36-fold).⁶

Information from mutagenesis experiments further suggests that AMDA and phenylalkylamines (i.e., **3**) or DOX analogues (i.e., **2**) with small 4-position substituents (e.g., DOB, DOI) bind differently, at least with respect to F340^{6,52}. In the current models, the side chain of F340^{6,52} is at the interface between TM5 and TM6, π -stacked with the side chain of F243^{5,47} (Figure 2A). Any effect that an F340 mutation might have on ligand affinity could either be due to changes in a direct, ligand–receptor van der Waals interaction or an indirect effect caused by a change in the shape of the helical bundle. The mutation F340L has been shown to decrease affinity of agonists but generally has no effect on the binding of classical antagonists.⁴¹ AMDA (**1a**) and the bromo analogue **1b** both bind to the mutant receptor equally well (3-fold decrease and no change in affinity, respectively) compared to their affinity at the wild type receptor (Table 2). The same mutation has little effect on ketanserin affinity but essentially abolishes DOI binding (an approximately 14000-fold decrease).⁴¹ This is entirely consistent with AMDA and AMDA derivatives binding in a completely different fashion from DOI, at least with respect to the F340^{6,52} position in the receptor structure. The affinities of the two 2,2-diphenylami-

noethane compounds (Table 2) are either unchanged or increased by F340L mutation (**4a**, $K_i = 4,140$ nM; **4b**, $K_i = 3.5$ nM) relative to the wild type (**4a**, $K_i = 4,610$ nM; **4b**, $K_i = 260$ nM). Again, these results support the notion that, with respect to F340, the diphenyl compounds (**4a,b**) behave differently from phenylethylamines and most likely bind in a mode distinct from that of the analogous tricyclic compounds **1a** and **1b**. Changes in the side chain conformation of F340 have been previously invoked to explain affinity enhancement for some classes of compounds with the F340L mutant.³⁰

Model Construction. In the following subsections, computationally derived 5-HT_{2A} GPCR models are described that separately model the binding characteristics of selected agonists and antagonists. “Agonist-biased” and “antagonist-biased” receptor models were generated in the following way: Using the MODELER software package, a population of 100 5-HT_{2A} conformationally distinct receptor models derived from bovine rhodopsin was generated. The automated docking program GOLD was then used to separately dock both stereoisomers of a high-affinity agonist (DOB, **2b**) and an antagonist (ketanserin) into each of the 100 5-HT_{2A} receptor models (Chart 1). On the basis of the quality of the docked receptor–ligand complexes and information from site-directed mutagenesis, one of the 100 models was selected to be the “agonist” 5-HT_{2A} receptor model and another was selected as the “antagonist” 5-HT_{2A} model (Supporting Information Figure 1). Both stereoisomers of each of the compounds listed in Table 1 were then docked into both the agonist and antagonist receptor models. Docking scores and information from mutagenesis data were then used to select the most appropriate receptor (agonist or antagonist) for each ligand.

Agonist Receptor Complex Models. Both isomers of DOB were found to favorably interact with the selected agonist receptor model and in a nearly identical fashion (Supporting Information Figure 2). The most significant difference in the binding modes of the stereoisomers is in the position of the protonated amine; however, both isomers are able to form a salt bridge with D155^{3,32}. The proposed binding pocket for *R*(–)-DOB (*R*(–)-**2b**) is shown in Figure 2A, and residues that can potentially interact with it are reported (Supporting Information Table 1). The aromatic ring is associated most closely with W336^{6,48}, F339^{6,51}, and F340^{6,52}. The 4-bromo substituent is oriented toward the interfacial region between TM5 and TM6 and the 2-methoxy group of DOB accepts a hydrogen bond from N343^{6,55}. The 5-methoxy group is near S159^{3,36}, T160^{3,37}, and S242^{5,46} and can potentially form hydrogen bonds with these residues to further stabilize the receptor–ligand complex. Additionally, a lipophilic interaction occurs between the methyl of the 5-methoxy group and W336^{6,48}. Other nearby aromatic residues that can potentially interact with the aromatic ring of DOB include F243^{5,47} and F340^{6,52}. F339^{6,51} is in a position to further stabilize the ammonium–D155^{3,32}–S159^{3,36} complex via a π –cation interaction.

Recently, it was reported⁴² that *R*(–)-DOB and *S*(+)-DOB both have high affinity for the 5-HT_{2A} receptor but with the *R*(–)-isomer showing a somewhat lower K_i than the *S*(+)-isomer (*R*(–)-DOB, $K_i = 0.29$ nM; *S*(+)-DOB, $K_i = 1.9$ nM). Employing modeling techniques, the authors showed that the *R* and *S* isomers of DOX phenylethylamines can bind in a very similar fashion but that the orientation of S239^{5,43}, F240^{5,44}, F243^{5,47}, F244^{5,48}, and F340^{6,52} differed depending on which isomer was docked into the receptor. Although our modeling technique places DOB in the same location as the previous authors, the model described here features a π -stacked interaction between F340^{6,52} and F243^{5,47}. Disruption of this associa-




Figure 2. The proposed binding mode of selected compounds docked and energy-minimized in the 5-HT_{2A} receptor models. Carbon atoms of the ligand are colored green. Residues whose heavy atoms fall within 4 Å of the bound ligand heavy atoms are displayed. A light-blue transparent trace indicates the position of the receptor backbone. Hydrogen bonding interactions are indicated with a thin black line, and H-bond donor–acceptor distances (in Å) are indicated in blue. The antagonist models are displayed from a common point of view in which TMs 6, 7 and 1 are closest to the viewer. (A) *R*(-)-DOB (*R*(-)-2b); agonist model. (B) Ketanserin; antagonist model. (C) AMDA (1a); antagonist model. (D) (*S*)-3-hydroxy-AMDA (1g); antagonist model. (E) (*S*)-3-phenylpropylAMDA (1c); antagonist model. (F) (*R*)-2c; antagonist model.


tion (either through a point mutation or via interactions with a ligand) may alter the location and orientation of the helices within the helix bundle. As mentioned by Parrish, et al.,⁴² the cognate residues in bovine rhodopsin, F212^{5,47} and A269^{6,52},

have been shown to have highly coupled evolution as part of a physically connected network that links distant functional sites in the tertiary structure of GPCRs.⁴³ The close association of the small-substituent DOX ligands with F340^{6,52} would also

Table 2. Effects of the 5-HT_{2A} Receptor F340^{6,52}L Mutation on Ligand Affinity

compd	<i>K_i</i> (nM) ^a	
	wild type	F340L
1a	20	57
1b	1.3	1.8
4a	4610	4140
4b	260	3.5
DOI	0.92	13700
ketanserin	0.4	0.23

^a *K_i* values at the wild type receptors are from Table 1. Standard errors typically range between 15% and 25% of the *K_i* value. [³H]Ketanserin labeled cloned 5-HT_{2A} sites.

Chart 1. Structures of AMDA (**1a**), DOB (**2b**), and Ketanserin

explain why the F340L mutation nearly abolished⁴⁴ the affinity of DOI for the 5-HT_{2A} receptor. Both enantiomers of DOB and DOI have a high affinity for the 5-HT_{2A} receptor⁴² and were docked into the agonist receptor model in a nearly identical manner, the only difference being the position of the α -methyl group (Supporting Information Figure 2). In our agonist receptor model, DOB occupies the same binding pocket that has been predicted for the endogenous ligand 5-HT.^{45–47}

The proposed binding mode for DOB features the ligand accepting a hydrogen bond from N343^{6,55}. An analysis of the primary sequences of the known human 5-HT receptor subtypes reveals that only 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C}, 5-HT₄, and 5-HT₆ receptors feature asparagine at 6.55, although other subtypes have side chains capable of donating a hydrogen bond at this position (6.55 = Ser in 5-HT_{1B}, 5-HT_{1D}, and 5-HT₇). The Psychoactive Drug Screening Program (PDSP) *K_i* Database (<http://pdsp.med.unc.edu/pdsp.php>) contains entries for DOB as the test ligand for 5-HT₁ and 5-HT₂ receptor subtypes. In all cases, the affinity of DOB for the 5-HT₂ subtypes was much greater (0.6 to 152 nM) than that for the 5-HT₁ subtypes (556–6327 nM). This is consistent with the hypothesis that N^{6.55} contributes significantly to the observed high affinity of DOB at the 5-HT₂ subtypes. The 6.55 position has also been shown to be important for the binding of other agonists and antagonists at serotonergic and other closely related aminergic GPCR subtypes.^{48–53}

The ligand-accessible and highly conserved residues W336^{6,48} and F340^{6,52} of the “aromatic cluster”⁵⁴ in site 1 have been proposed to be part of a rotameric “toggle switch”^{35,55} in which the χ_1 torsion angles of these residues determine, in conjunction with the proline kink in TM6, the proximity of the intracellular ends of TM3 and TM6 (i.e., the “ionic lock”⁵⁶). The χ_1 conformations that correspond to the “activated” receptor are trans for both 6.48 and 6.52, which is consistent with the putative agonist model presented here. Taken together, this information along with the examples given above provide additional evidence that the agonist model described here is accurate.

AMDA (**1a**) was successfully docked into site 1 in the agonist model with the basic amine H-bonded to both D155^{3,32} and S159^{3,36}. One of the aromatic rings is oriented toward the cluster of hydrophobic residues on TM6, interacting with I163^{3,40}, F243^{5,47}, W336^{6,48}, and F340^{6,52}; the second aromatic ring of AMDA interacts with V156^{3,33}, I206^{4,56}, and L229^{x12,52}. Importantly, it is shown here (Table 2) that mutation of F340^{6,52} to leucine has little effect on the binding of antagonists like AMDA (**1a**). In contrast, the F340^{6,52}L mutation had dramatic effects on the binding of DOI, an agonist very similar to DOB (**2b**). This would indicate that **1a** and **2b** bind differently with respect to F340^{6,52}.

AMDA analogues with small substituents at the 3-position (**1b,e,g**) are oriented in site 1 in a manner analogous to that of AMDA. However, for **1e** and **1g**, there are no nearby H-bond donors or acceptors to effectively interact with the polar functionality at the 3-position (W336^{6,48} is close, but with poor H-bond geometry). For the larger, more flexible hydrophobic analogues (**1c,d,f**), the 3-position substituent is either directed toward the opening of the receptor cavity (for *S*-isomers) or folds back onto the dihydroanthracene core (for *R*-isomers), a characteristic that is statistically unlikely based upon an analysis of crystal structures of ligand–receptor complexes.^{57,58} In the phenylisopropylamine series, DOB analogues with small substituents at the 4-position (**2a,e,g**) dock into the receptor in a similar fashion as DOB, with the aromatic ring associated with W336^{6,48}, F339^{6,51}, and F340^{6,52} and the methoxy groups interacting with S159^{3,36}, T160^{3,40}, S242^{5,46}, and N343^{6,55}. The position of the aromatic ring for these compounds is close to the position of the aromatic ring in AMDA most closely associated with the aromatic cluster on TM6. As with the AMDA analogues substituted with small polar substituents at the 3-position, there is no H-bonding partner for the small polar substituents at the 4-position of the DOB analogues. This is consistent with the low observed binding affinities for these compounds. For DOB analogues **2c** and **2d**, the large 4-position substituents are folded back onto the ligand’s aromatic ring (both isomers), analogous to the AMDA analogues (*R*-isomer) with large 3-position substituents. To accommodate the bulk of the large substituent, the aromatic ring is displaced toward TM4 and the H-bonds with the methoxy groups are diminished or eliminated. The phenylethylamine analogues **3a–d** dock with conformations that are similar to their corresponding DOB analogues, and the diphenylmethylaniline analogues **4a, 4b**, and **4d** dock in the receptor like their corresponding AMDA analogues **1a, 1b**, and **1d**.

Antagonist Receptor Complex Models. The energy-minimized ketanserin–receptor model is depicted in Figure 2B (nearby residues are listed in Supporting Information Table 1). In addition to the hydrogen bond formed between the ammonium ion in the ketanserin piperidine ring and the conserved D155^{3,32}, three other hydrogen bonds are evident: S131^{2,61} bonds with the *p*-fluorobenzoyl carbonyl oxygen, S159^{3,36} bonds with the N1 quinazolinone nitrogen atom, and S373^{7,46} bonds with the carbonyl oxygen at position 2 of the quinazolinone ring system (Figure 2B). Hydrophobic residues surrounding the remainder of the ligand include W151^{3,28}, I152^{3,29}, V156^{3,33}, L229^{x12,52}, W336^{6,48}, V366^{7,39}, W367^{7,40}, and Y370^{7,43}.

To provide an indication of the correctness of the docked solution, relevant mutagenesis binding data were collected from the literature; these are listed in Table 3. As [³H]ketanserin is often used as the radioligand in competitive binding assays involving the 5-HT_{2A} receptor and its mutants, *K_d* values were frequently available. Many of the mutations listed in Table 3

Table 3. Effect of Various Mutations on the Binding Affinity of Ketanserin for 5-HT_{2A} Mutants

mutation	effect	ref	comments ^a
W76 ^{1,34} A	10-fold ↓ in affinity	44	interacts with W367 ^{7,40}
D120 ^{2,50} N	10-fold ↓ in affinity	105	widely conserved across GPCRs
F125 ^{2,55} L	no effect	104	not in binding pocket
F125 ^{2,55} L	no effect	44	not in binding pocket
F125 ^{2,55} L	no effect	106	not in binding pocket
F125 ^{2,55} S	2-fold ↓ in affinity	104	not in binding pocket
F125 ^{2,55} S	no effect	107	not in binding pocket
M132 ^{2,62} L	no effect	107	not in binding pocket
T134 ^{2,64} A	no effect	107	Inaccessible when e2 loop is in cavity.
D155 ^{3,32} A	no detectable binding	108	ammonium binding site
D155 ^{3,32} E	no detectable binding	108	ammonium binding site
D155 ^{3,32} N	75-fold ↓ in affinity	105	ammonium binding site
D155 ^{3,32} N	no detectable binding	108	ammonium binding site
D155 ^{3,32} Q	no detectable binding	108	ammonium binding site
S159 ^{3,36} A	no effect	45	one turn below D155 ^{3,32}
S159 ^{3,36} C	no effect	45	one turn below D155 ^{3,32}
D172 ^{3,49} N	no effect	105	conserved D/ERY motif
W200 ^{4,50} A	no effect	44	widely conserved; not in binding site
S239 ^{5,43} A	<2-fold ↓ in affinity	47	in site 1
F240 ^{5,44} A	2-fold ↓ in affinity	47	not in binding pocket
S242 ^{5,46} A	~2-fold ↓ in affinity	109	in site 1
F243 ^{5,47} A	4.5-fold ↓ in affinity	47	interacts with F340 ^{6,52}
F244 ^{5,48} A	2-fold ↓ in affinity	47	not in binding pocket.
W336 ^{6,48} A	900-fold ↓ in affinity	44	"toggle switch"; site 1/site 2.
F339 ^{6,51} A	10-fold ↓ in affinity	104	one turn above W336 ^{6,48}
F339 ^{6,51} L	25-fold ↓ in affinity	104	one turn above W336 ^{6,48}
F339 ^{6,51} L	8-fold ↓ in affinity	44	one turn above W336 ^{6,48}
F339 ^{6,51} L	25-fold ↓ in affinity	106	one turn above W336 ^{6,48}
F339 ^{6,51} L	20-fold ↓ in affinity	107	one turn above W336 ^{6,48}
F339 ^{6,51} Y	7-fold ↓ in affinity	104	one turn above W336 ^{6,48}
F340 ^{6,52} A	2-fold ↓ in affinity	104	interacts with F243 ^{5,47}
F340 ^{6,52} L	no effect	104	interacts with F243 ^{5,47}
F340 ^{6,52} L	2-fold ↓ in affinity	44	interacts with F243 ^{5,47}
F340 ^{6,52} L	no effect	107	interacts with F243 ^{5,47}
F340 ^{6,52} L	2-fold ↓ in affinity	106	interacts with F243 ^{5,47}
F340 ^{6,52} Y	70-fold ↓ in affinity	104	interacts with F243 ^{5,47}
F365 ^{7,38} L	4-fold ↓ in affinity	44	not in binding site
W367 ^{7,40} L	no detectable binding	44	interacts with W76 ^{1,34}
Y370 ^{7,43} A	18-fold ↓ in affinity	44	in site 2
F383A	3.5-fold ↓ in affinity	44	in the turn between TM7 and helix 8

^a Comments refer to the antagonist model described here.

involve residues that are not located in the binding crevice of the receptor. Others involve residues that are conserved across all GPCRs and are probably required to maintain the structural integrity and/or basic functioning of the receptor. Several of the mutations involve the conserved aspartate D155^{3,32}, and the result of mutating this residue to something other than aspartate is a near or complete loss of affinity for ketanserin. Presumably, this mutation would also disrupt the binding of many other small basic amine-containing compounds, agonists and antagonists alike. Other mutations are more relevant to the binding of ketanserin itself. Mutation of serines S239^{5,43} and S242^{5,46} on TM5 to alanine has no significant effect upon the binding of ketanserin. This is consistent with the proposed model, as ketanserin does not approach TM5. The F243^{5,47} and F340^{6,52} mutations each minimally decrease the binding of ketanserin. While neither F243^{5,47} nor F340^{6,52} are within van der Waals interaction distance with ketanserin, the small decreases in affinity at these mutated positions could be accounted for by

indirect destabilization of the binding site. The S159^{3,36}A and S159^{3,36}C mutations were found to have almost no effect on the affinity of ketanserin. While this may seem to contradict our proposed model because S159^{3,36} participates in a hydrogen bond, the actual situation is probably more subtle. For example, it has been shown⁵⁹ that the entire quinazolinedione ring system may be replaced with a phenylethyl fragment lacking H-bonding capability without significant loss of affinity (less than 2-fold decrease in K_i). If ketanserin binds as proposed, then this would suggest that the hydrogen-bonding capability of S159^{3,36} is not required and thus consistent with the mutagenesis data. W336^{6,48}A was found to have one of the largest effects on ketanserin binding (a 900-fold decrease). This is consistent with the model because there is a substantial amount of hydrophobic surface contact area between the quinazolinedione ring system and the indole ring of W336^{6,48}. Similarly, mutation of F339^{6,51} to alanine or leucine results in moderate decrease (8- to 25-fold) in ketanserin's binding affinity due to the loss of hydrophobic bulk in the region. The F339^{6,51}Y mutation introduces a phenolic group into an area occupied by the fused phenyl ring of the quinazolinedione moiety, resulting in a moderate decrease in binding affinity. Mutation of F340^{6,52} to alanine or leucine has no significant effect. This is also consistent with the model because this residue is at a distant location in site 1 and is not expected to interact with ketanserin. The effect of the F340^{6,52}Y mutation is substantial, with a 70-fold decrease in binding affinity. Mutation to tyrosine at this position would introduce a hydroxyl group into the lipid bilayer. This could possibly facilitate the disruption of the F243^{5,47}–F340^{6,52} interaction and the binding cavity as a result because the tyrosine OH group would presumably prefer to be located in the more polar interior of the receptor. The W367^{7,40}L mutation abolished ketanserin binding and nearly abolished the binding of small agonists like 5-HT and DOM that would be expected to bind completely within site 1.⁴⁴ As well as providing a site of interaction for ketanserin, this would seem to indicate that W367^{7,40} forms part of an extended site 1, as mentioned earlier. Alternatively, W367^{7,40} may also interact with W76^{1,34}. Such an interaction may serve to stabilize the helical bundle, at least for the serotonin receptor subtypes, in which tryptophan is uniformly conserved at the 7.40 position, and a hydrophobic residue (tryptophan for the 5-HT₂ subtypes) appears at the 1.34 position in all but the 5-HT_{1D} receptor (serine for 5-HT_{1D}). Finally, the Y370^{7,43}A mutation decreases ketanserin's affinity by nearly 20-fold. This seems reasonable, considering the relatively close proximity of Y370^{7,43} to the piperidine ring of the ligand. In summary, these results are consistent with our proposed binding mode for the antagonist ketanserin.

Our approach in selecting a receptor for antagonists involved choosing the most highly ranked (as measured by the ChemScore fitness function) receptor–ligand complex that exhibited reasonable conformations for both ligand and receptor; in this particular case, the ketanserin test ligand adopted a twist-boat conformation. Twist-boat forms of cyclohexane are known to have energies that are about 5.5 kcal/mol higher than the corresponding "chair" forms;⁶⁰ those for piperidine would be expected to exhibit a similar increase in energy. At first glance, then, this particular docked solution for ketanserin may seem unreasonable. However, it has been noted that in many cases, the conformation of the bound ligand is one that may not even be close to a local energy minimum.^{57,58,61,62}

Very recently, Dezi, et al.⁶³ have generated a 5-HT_{2A} model suited to the binding of butyrophenone antipsychotics using methodology that is quite similar to that described here. In their

study, they present a ketanserin binding mode that is essentially “backwards” when compared to the ketanserin model proposed here (i.e., the *p*-fluorobenzoyl group is oriented toward TM5 instead of toward TM2). However, the authors go on to mention that there are likely to be multiple binding modes that contribute to the observed affinity for slender, roughly symmetric ligands (wherein a centrally positioned cation is flanked by two sets of roughly equivalent hydrogen bonding groups) such as ketanserin and the butyrophenones. Indeed, in our own experience, the GOLD-derived solutions for ketanserin usually dock in either of these two major orientations. Thus, it is possible that there exist alternate valid docked solutions for ketanserin.

Qualitatively, ketanserin and 3-phenylpropyl-AMDA (**1c**) are docked in much the same way (Figure 2E), with the *p*-fluorobenzoyl group occupying nearly the same region of space as the phenyl group of the phenylpropyl substituent of **1c**, and the quinazolinone ring system is in roughly the same area as the tricyclic ring system of **1c** (the rings of **1c** are oriented toward TM6; the ketanserin quinazolinone rings are oriented toward TM5). Significantly, all four isomers of **1c** (most likely acting as antagonists) received very high scores when docked into the ketanserin-selected antagonist model (Supporting Information Figure 3), indicating that both ketanserin and **1c** can recognize and engage the same receptor conformation.

The docked and minimized AMDA-5-HT_{2A} antagonist model is depicted in Figure 2C (nearby residues are listed in Supporting Information Table 1). When compared to 5-HT and traditional phenylethylamine-derived agonists, AMDA lacks both agonist-like functional groups (e.g., the 5-OH group of 5-HT or the 2,5-dimethoxy substituents of DOB) and presents an added feature, the “second” aromatic ring. The shape of the binding pocket in the antagonist receptor model exquisitely compliments the general shape of the AMDA molecule and that of its tricyclic core in particular (Figure 1B). The AMDA molecule is situated in the receptor in a distinctly different location than DOB, although AMDA and DOB do interact with common residues on TM3 (D155^{3,32}) and TM6 (Y339^{6,51}). Effectively situated between TM3 and TM7, AMDA binds in the receptor such that one aromatic ring orients toward TM6 and the other is oriented toward TM1. The ammonium group of AMDA interacts with D155^{3,32} and also can interact (as suggested by molecular dynamics experiments) with the backbone carbonyl oxygen atom of C227^{x12,50}, one of the cysteines of the disulfide bridge anchoring the e2 loop to the extracellular end of TM3. The aromatic ring that is oriented toward TM1 is sandwiched between W151^{3,28} and Y370^{7,43}; the ring oriented toward TM6 forms π - π interactions with D155^{3,32}. The docked AMDA solution also forms close hydrophobic contacts with V366^{7,39}, which could have implications for the selectivity of AMDA for 5-HT_{2A} over the dopaminergic D₂ receptor (vide infra).

Site 2 is lined most notably with several polar residues (T81^{1,39}, S131^{2,61}, S159^{3,36}, S373^{7,46}) and hydrophobic residues (M128^{2,58}, W151^{3,28}, V366^{7,39}, Y370^{7,43}). The distribution of polar and hydrophobic residues is such that an amphiphilic cavity is created between the relatively polar faces of TM1 and TM2 and the lipophilic face of TM7. It is possible that the amphiphilic nature of the site is the characteristic that allows both relatively polar (e.g., **1e,g**), nonpolar (e.g., **1c,d**), and mixed (e.g., **1f**) groups to bind with reasonably high affinity almost without discrimination, as described in the following paragraphs.

The 3-position substituents of AMDA are directed either toward TM1 and TM2 (for *S*-isomers) or toward TM3 and TM6 (for *R*-isomers). The tricyclic core of the AMDA analogues with small substituents (**1b,e,g**) adopts a position in site 2 that is the

same as for the parent AMDA. For the small polar groups (**1e,g**), H-bonding takes place with either T81^{1,39} and S131^{2,61} (*S*-isomers) or with S159^{3,36} and S373^{7,46} (*R*-isomers). The top-ranked GOLD-docked solution for (*S*)-**1g** features a hydrogen bond to both T81^{1,39} and S131^{2,61} (Figure 2D). The more elongated shape of site 2 relative to site 1 allows for larger 3-position substituents (**1c,d,f,h**) to dock in a more fully extended conformation. For *S*-isomers, the substituent is directed toward and interacts with Y370^{7,43}. To accommodate the large substituent, the tricyclic core is shifted away from the e2 loop and toward site 1. This is possible due to the basic amine's ready accessibility to both side chain oxygen atoms on D155^{3,32}. The docked and minimized (*S*)-3-phenylpropyl-AMDA (**S-1c**) interaction model is depicted in Figure 2E (nearby residues are listed in Supporting Information Table 1). The tricyclic core of compound **1c** interacts with residues on TM3 (D155^{3,32} and S159^{3,36}) and on TM6 (M335^{6,47}, W336^{6,48}, and F339^{6,51}). The bulky 3-position substituent is located in the cavity bounded by TM1, TM2, and TM7 (site 2), with the aromatic portion anchored at Y370^{7,43}. For *R*-isomers with large 3-position substituents, the *R*-group is either directed toward S159^{3,36}, W336^{6,48}, and M365^{6,47} (**1d,f**) or the AMDA core is inverted in an “upside-down” fashion, with the *R*-group interacting with Y370^{7,43} as described for the *S*-isomers (**1c**).

The bis-substituted compound **1h** (Table 1) was initially evaluated in an attempt to bridge and interact simultaneously with both sites 1 and 2. The 6-methoxy group was expected to interact with a hydrogen bond donating residue of site 1, with the *n*-hexyl group anchored in site 2. While monosubstitution with either an *n*-hexyl (K_i = 7.0 nM, **1d**) or a methoxy group (K_i = 7.5 nM, **1e**) enhances affinity relative to AMDA (K_i = 20 nM, **1a**) to a small extent, the bis-substituted compound (K_i = 43 nM, **1h**) has a lower affinity than either the unsubstituted compound (**1a**) or the monosubstituted derivatives (**1c,d**). At the very least, the bifunctional nature of **1h** does not greatly enhance affinity. The docked solution of (*R*)-**1h** (not shown) in the antagonist model reveals that the ligand primarily occupies site 2 and that the *n*-hexyl group is situated in a similar fashion to the phenylpropyl group of (*S*)-**1c**. The methoxy group of (*R*)-**1h** is directed toward TM6 and interacts with M335^{6,47}, but there are no H-bond donors nearby with which the methoxy oxygen can interact. For (*S*)-**1h**, the positions of the substituents are reversed: the methoxy group H-bonds with T81^{1,39} and/or S131^{2,61} and the *n*-hexyl group is associated with W336^{6,48} and M335^{6,47}.

DOB-like isopropylamines with small substitutions at the 4-position of the phenyl ring (**2a,b,e,g**) are docked into the antagonist model such that the aromatic ring is situated between W151^{3,28} and Y370^{7,43}. Those that are nonpolar (**2a,b**) orient either the 2-methoxy group toward S226^{x12,49} or the 5-methoxy group toward S77^{1,35} (both isomers). Those that are polar (**2e,g**) orient the 4-substituent to interact with either T81^{1,39} or S131^{2,61} (both isomers). DOB-like isopropylamines with large substituents at the 4-position place the phenyl ring between D155^{3,32} and V366^{7,39} (both isomers) as depicted in Figure 2F for compound (*R*)-**2c**. Such compounds are stabilized in the binding site via hydrogen bonds with D155^{3,32} and S159^{3,36} (ligand ammonium group) as well as W151^{3,28} and S226^{x12,49} (5-methoxy group), although the latter H-bonds are far from ideal. An intramolecular hydrogen bond is also possible between the 2-methoxy group oxygen atom and the ammonium group. The large 4-position substituent is directed toward the same pocket in site 2 as large 3-position substituents of the AMDA analogues and is stabilized in an analogous manner. Supporting Information

Table 4. Receptor and Transporter Selectivity for Compounds **1a**, **1b**, and **1d**

compd	K _i , nM (±SEM)				
	5-HT _{2A} ^a	5-HT _{2C} ^b	D ₂ ^c	SERT ^d	NET ^e
1a ^f	20	43 (5)	> 10000	> 10000	> 10000
1b	1.3	3.3 (0.4)	> 10000	1200 (160)	4490 (1080)
1d	7.0	62 (6)	6280 (820)	490 (9)	845 (270)

^a Radioligand [³H]ketanserin. ^b Radioligand [³H]mesulergine. ^c Radioligand [³H]spiperone. ^d Radioligand [³H]paroxetine. ^e Radioligand [³H]nisoxetine. ^f Data from ref 6.

Figure 4 shows the similarity in binding modes of **1c** and **2c** in the antagonist receptor binding site. The lack of H-bonding with the methoxy groups is consistent with the observation that they are not needed when the 4-position is phenylpropyl.¹⁵ The phenylethylamine derivatives **3a–d** dock into site 2 in the same way as do the isopropylamine analogues **2a–d**, and the diphenylmethylamine derivatives (**4a,b,d**) dock similarly to their respective AMDA derivatives.

There is very little mutagenesis data available to lend insight into the nature of the interaction between the AMDA class of compounds and the 5-HT_{2A} receptor specifically. However, residues that contribute to the amphiphilic nature of site 2 and have been implicated to be important for the binding of ligands into the antagonist model have also been implicated to be important for ligands binding in other closely related aminergic GPCRs. These include the residues at positions S131^{2,61,64,65}, W151^{3,28,65–68}, Y370^{7,43,44,69–71} and V366^{7,39,68,72–78}. Once again, when taken together, these examples provide evidence that site 2 is accessible in the 5-HT_{2A} receptor and that the antagonist model described here is accurate.

The results of the docking experiments may be summarized as follows: Each of the tested compounds containing a phenylpropyl, *n*-hexyl, or *n*-pentyloxy group exhibited significant binding affinity (*K_i* ≤ 200 nM), and it was these compounds that tended to show the greatest preference for site 2 (antagonist model) over site 1 (agonist model) based on the ChemScore fitness function used by the GOLD docking program (Supporting Information Table 2). Compound **2c** has been shown to have antagonist character,¹⁵ which is consistent with its preference for the antagonist model. The relatively high affinity of AMDA derivatives with small polar substituents (**1e,g**) is likely due to the stabilization of both isomers in the amphiphilic site 2. The high-affinity compounds with small nonpolar R-groups (**1a,b, 2b**) tended to favor the agonist model to a greater degree. This makes sense for the agonist **2b**, where there is more extensive and effective hydrogen bonding with the methoxy groups, which have been shown to be necessary for high affinity in these compounds.^{13,15} In addition, the F340^{6,52}L mutation has been shown to abolish the affinity of DOI, a compound closely related to **2b** (DOB). The preference of the antagonist **1a** for site 1 may be an anomaly, however, because the AMDA core is in close proximity to F340^{6,52}, yet the F340^{6,52}L mutation has little effect on its binding affinity. Similarly, **4b** may actually bind in site 1 rather than in site 2, as predicted from the fitness function. Further mutagenesis testing and functional assays will be necessary, however, in order to unequivocally resolve the binding modes of these compounds.

Receptor Selectivity. As shown in Table 4, AMDA and two of its high affinity analogues are quite selective for 5-HT₂ receptors. 5-HT_{2A} affinity is between 900- and 7000-fold higher than D₂ receptor affinity. There is little selectivity for 5-HT_{2A} versus 5-HT_{2C} receptors (2- to 9-fold). Selectivity for the 5-HT_{2A} receptor over the serotonin and norepinephrine transporters is pronounced for **1a** and **1b** (between 500- and 3000-fold) and

less pronounced for **1d** (60- and 120-fold). Because selectivity against the D₂ receptor is not strongly influenced by the nature of the 3-position substituent, the observed selectivity is probably attributable to the AMDA nucleus itself. Examination of the docked AMDA structure (Figure 2C) along with an alignment of the 5-HT_{2A} and D₂ receptor sequences (Figure 3) allows the identification of residues that are likely responsible for the selectivity of AMDA for the 5-HT_{2A/C} receptors. Residues in the antagonist model that possess a heavy atom within a 4.5 Å radius of any heavy atom in AMDA are highlighted in yellow boxes in Figure 3. Within this set of residues, one variant position in TM1 (S77^{1,35}), one position in TM2 (S131^{2,61}), three in TM3 (W151^{3,28}, I152^{3,29} and S159^{3,36}), one in the e2 loop (S226^{x12,49}), and one in TM7 (V366^{7,39}) that face the central cavity of the 5-HT_{2A} receptor model can be identified. It is possible that each of these residues contribute to the selectivity of ligands for 5-HT_{2A} over D₂. The cognate residue of S77^{1,35} in the 5-HT_{2A} receptor is Y37^{1,35} in the D₂ receptor. The additional steric bulk of the tyrosine side chain (compared to serine) would be sufficient to displace AMDA from its preferred binding site. The cognate residue of W151^{3,28} in the D₂ receptor is F110^{3,28}. Although tryptophan and phenylalanine are both aromatic, the close association of the side chain at this position with the aromatic ring system of AMDA (3.6 Å) would suggest that even small differences in side chain topology could take on greater significance for binding. S226^{x12,49}, whose equivalent residue in D₂ is E181^{x12,49}, is adjacent to the disulfide bond anchoring the e2 loop to the top of TM3. In this position, the side chain of a glutamic acid residue could extend into AMDA's proposed binding site, placing its polar carboxyl group in approximately the same location as one of the aromatic rings of AMDA. Perhaps the most influential residue in determining 5-HT_{2A/C/D2} selectivity is V366^{7,39}, which is equivalent to position T412^{7,39} of the D₂ receptor, and whose side chain heavy atoms are within 4 Å of three heavy atoms (3.54, 3.85, and 3.93 Å) of the site 2 aromatic ring system of AMDA in the antagonist model. As mentioned earlier, in adrenergic receptors, the presence of an alanine or threonine instead of the asparagine residue at this position has been shown to be responsible for subtype selectivity within the serotonin receptor family, particularly with respect to the ability to bind β-adrenergic antagonists such as propranolol.^{72,73} It is possible that placement of a polar threonine near the AMDA aromatic ring may be unfavorable enough to account for the lower affinity of AMDA and AMDA derivatives with the D₂ receptor. This hypothesis could be tested by evaluation of the V366T mutant of the 5-HT_{2A} receptor.

Conclusion

Previous investigations have provided evidence that phenylalkylamines can be agonists or antagonists depending on the nature of the 4-position substituent.^{13,15} It has been speculated that the difference in functional behavior is a reflection of the possibility that agonist and antagonist phenylalkylamines bind in a different fashion with the 5-HT_{2A} receptor. A comparison of the effects of a parallel series of aromatic substituents based on the tricyclic 5-HT_{2A} antagonist AMDA suggests that the AMDA series may bind in a fashion similar to that of antagonist phenylalkylamines with bulky aromatic substituents. Differential effects of the F340L mutation observed for the AMDA series and phenylethylamine agonists supports this hypothesis. Automated docking studies with ligands docked into 5-HT_{2A} models are consistent with the hypothesis that agonists bind such that the aromatic rings are oriented toward the fifth and sixth




Figure 3. Alignment of the bovine rhodopsin, 5-HT_{2A}, and D₂ receptor sequences. Sequence positions highlighted in red indicate highly conserved amino acids among the class A GPCR family that serve as reference positions in the general Ballesteros–Weinstein¹¹⁰ numbering system. Traditional numbering is also given for the 5-HT_{2A} (top) and D₂ (bottom) sequences. Bovine rhodopsin residues highlighted in green indicate positions that are within 12.0 Å of bound retinal; these were mutated to alanine prior to the 3-D model building phase. Bovine rhodopsin residues highlighted in purple indicate positions in the third intracellular loop that were mutated to glycine in the 5-HT_{2A} sequence and in subsequent 5-HT_{2A} models. Residues highlighted in yellow boxes in the 5-HT_{2A} sequence represent those that are closest to AMDA (within 4.5 Å heavy atom to heavy atom) in the antagonist model. Note: the D₃, M₁, V_{1a}, β₂, and δ-opioid GPCR sequences have been omitted for brevity and clarity (see text for details). The figure was created using ALSCRIPT.¹¹¹

transmembrane helices (site 1), a region of limited bulk tolerance, whereas antagonists place the substituted aromatic ring near the seventh and toward the first, second, and seventh transmembrane helices (site 2) in a region of greater bulk tolerance. AMDA and two substituted derivatives were found have a high degree of selectivity against the D₂ receptor and the serotonin (SERT) and norepinephrine (NET) transporters but were nonselective with respect to the 5-HT_{2C} receptor. Analysis of the putative binding modes of AMDA and related derivatives indicate that a valine/threonine exchange between 5-HT_{2A/C} and D₂ receptors contributes significantly to the observed selectivity of these compounds.

Experimental Methods

Synthesis. Melting points were determined using a Thomas–Hoover melting point apparatus and are uncorrected. Proton magnetic

resonance (¹H NMR and ¹³C NMR) spectra were obtained with a Varian Gemini 300 spectrometer using tetramethylsilane as an internal standard. Infrared spectra were recorded on a Nicolet Avatar 360 ESP FT-infrared spectrometer. Elemental analysis was performed by Atlantic Microlab, Inc., and determined values are within 0.4% of theory (Supporting Information Table 3). Thin-layer chromatography (TLC) was performed using silica gel-coated GHLF plates (250 μm, 2.5 cm × 10 cm, Analtech, Inc., Newark, DE). Anhydrous solvents were purchased and stored under nitrogen over molecular sieves. Medium pressure column chromatography was carried out using Silica gel 60, 0.040–0.063 mm, (230–400 mesh), Lancaster Synthesis.

3-Bromo-9-aminomethyl-9,10-dihydroanthracene hydrochloride (1b). Tin(II) chloride dihydrate (1.06 g, 4.70 mmol) was added to a well stirred solution of 3-bromo-9-nitromethyl-9,10-dihydroanthracene (**8**, 0.300 g, 0.940 mmol) in absolute EtOH (3 mL). The suspension was heated at 70 °C on an oil bath (5 h). The

resulting bright-yellow solution was allowed to cool to room temperature and the solvent removed under reduced pressure to provide a yellow oil. The oil was dissolved in EtOAc (10 mL), sat NaHCO₃ solution (5 mL) was added, the suspension was filtered, and the filter cake was washed with EtOAc (5 × 30 mL). The filtrate was collected, H₂O (20 mL) was added, and the mixture was extracted with EtOAc. The EtOAc portion was washed with H₂O (2 × 20 mL) and brine (20 mL), dried (MgSO₄), and concentrated under reduced pressure to provide a viscous yellow oil. The resulting yellow oil was purified using medium pressure column chromatography (CH₂Cl₂/MeOH, 9:1) to provide an opaque semisolid. The semisolid was dissolved in EtOAc (10 mL) and ethereal HCl was added until no further precipitate formed. The resulting suspension was filtered and washed with EtOAc to provide a white solid that was recrystallized from MeOH/CHCl₃ to provide **1b** (0.10 g, 33%) as white crystals; mp 282–284 °C dec. ¹H NMR (DMSO-*d*₆) δ 2.92–2.95 (d, *J* = 8 Hz, 2H, CH₂–NH₃), 3.92–3.98 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.12–4.19 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.28–4.34 (t, *J* = 8 Hz, 1H, Ar–CH). Anal. (C₁₅H₁₄N·HCl·0.25 H₂O) C, H, N.

3-(3-Phenylpropyl)-9-aminomethyl-9,10-dihydroanthracene fumarate (1c). Compound **1c** was prepared from **15** in a manner analogous to **1e**. The fumarate salt was recrystallized from acetone/CHCl₃ to provide **1c** (0.042 g, 13%) as pale-yellow crystals; mp 172–175 °C. ¹H NMR (DMSO-*d*₆) δ 1.83–1.93 (m, 2H, CH₂), 2.56–2.63 (m, 4H, Ar–CH₂), 2.82–2.85 (d, *J* = 8 Hz, 2H, CH₂–NH₂), 3.83–3.89 (d, *J* = 18 Hz, 1H, Ar–CH₂–Ar), 4.06–4.12 (d, *J* = 18 Hz, 1H, Ar–CH₂–Ar), 4.12–4.17 (t, *J* = 8 Hz, 1H, Ar–CH–Ar), 6.48 (s, 2H, fumarate), 7.05–7.43 (brm, 12H, Ar–H). Anal. (C₂₄H₂₅N·C₄H₄O₄·0.25 acetone) C, H, N.

3-*n*-Hexyl-9-aminomethyl-9,10-dihydroanthracene fumarate (1d). 2-Amino-1-(2-benzyl-4-*n*-hexylphenyl)-1-ethanol oxalate (**20d**, 0.350 g, 1.13 mmol) was added to PPA (10.0 g), and the viscous mixture was stirred at room temperature by hand for 30 min. Water (100 mL) was slowly added, and the mixture was made basic to pH 12 with sat NaHCO₃. The aqueous solution was extracted with EtOAc (3 × 70 mL), and the organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography (CH₂Cl₂/MeOH, 9:1) to provide **1d** (0.100 g, 30%) as a pale-orange oil. The oil was dissolved in anhydrous acetone (20 mL), and anhydrous fumaric acid (0.030 g, 0.340 mmol) was added. The mixture was heated until the solid dissolved and the mixture was then cooled and filtered to provide **1d** (0.070 g, 15%) as a white powder; mp 185–186 °C. ¹H NMR (DMSO-*d*₆) δ 0.85–0.86 (s, 2H, CH₃), 1.24 (brs, 6H, CH₂), 1.55–1.62 (m, 2H, CH₂), 2.52–2.57 (t, *J* = 8 Hz, 2H, CH₃), 2.83–2.85 (d, *J* = 8 Hz, 2H, CH₂–NH₂), 3.82–3.88 (d, *J* = 18.5 Hz, 1H, Ar–CH₂–Ar), 4.06–4.12 (d, *J* = 18.5 Hz, 1H, Ar–CH₂–Ar), 4.12–4.19 (t, *J* = 7 Hz, 1H, Ar–CH–Ar), 6.45 (s, 2H, fumarate), 7.05–7.38 (brm, 7H, Ar–H). Anal. (C₂₁H₂₇N·C₄H₄O₄·0.25 H₂O) C, H, N.

3-Methoxy-9-aminomethyl-9,10-dihydroanthracene fumarate (1e). 2-Amino-1-[2-(3-methoxybenzyl)phenyl]-1-ethanol oxalate (**20e**, 0.130 g, 0.370 mmol) was added to a well-stirred solution of Eaton's reagent (20 mL) under N₂. The mixture was allowed to stir (1 h), and water (50 mL) was added. The suspension was made basic to pH 13 with 10% NaOH and extracted with EtOAc (3 × 35 mL). The extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a pale-yellow oil (0.080 g, 0.330 mmol). The oil was dissolved in anhydrous 2-PrOH, and fumaric acid (0.0420 g, 0.360 mmol) was added. The suspension was heated until all of the solid dissolved, allowed to cool to room temperature, and concentrated under reduced pressure. The solid residue was then recrystallized (EtOAc/2-PrOH) to provide **1e** (0.060 g, 45%); mp 195–197 °C. ¹H NMR (CD₃OD) δ 2.79–2.82 (d/d, *J* = 8 Hz, 2H, CH₂–NH₂), 3.58 (s, 3H, OCH₃), 3.65–3.71 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 3.88–3.94 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 3.98–4.2 (t, *J* = 8 Hz, 1H, Ar–CH–Ar), 6.47 (s, 2H, Fumarate), 6.62–6.64 (d, *J* = 8 Hz, 1H, Ar–H), 6.72 (s, 1H, Ar–H), 7.04–7.12 (brm, 5H, Ar–H). ¹³C NMR (CD₃OD) δ 36.49, 45.51, 46.08, 56.30, 114.05, 115.26, 128.46, 129.0, 129.16,

129.78, 129.98, 130.83, 136.79, 137.56, 138.51, 140.08. Anal. (C₁₆H₁₇NO·C₄H₄O₄) C, H, N.

3-*n*-Pentyloxy-9-aminomethyl-9,10-dihydroanthracene fumarate (1f). 2-Amino-1-[2-[3-(*n*-pentyloxy)benzyl]phenyl]-1-ethanol oxalate (**20f**, 0.500 g, 1.16 mmol) was added to methanesulfonic acid (20 mL) under N₂. The suspension was allowed to stir at room temperature (2 h), and water (50 mL) was added. The suspension was made basic to pH 13 with 10% NaOH and extracted with EtOAc (3 × 50 mL). The combined extracts were washed with water and brine, dried (MgSO₄), and concentrated to provide a brown oil. The oil was purified using medium pressure column chromatography (CH₂Cl₂/MeOH, 9:1) to provide a yellow oil (0.190 g, 55%). The fumarate salt was prepared by adding fumaric acid (0.750 g, 0.650 mmol) to the amine in 2-PrOH (30 mL). The suspension was heated until the solid dissolved, cooled, and then filtered. The yellow solid was recrystallized from EtOAc/2-PrOH to provide **1f** (0.210 g, 44%) as pale-yellow crystals; mp 178–180 °C. ¹H NMR (CD₃OD) δ 0.70–0.75 (t, *J* = 7 Hz, 3H, CH₃), 1.16–1.26 (m, 4H, CH₂), 1.50–1.57 (m, 2H, CH₂), 2.84–2.87 (d, *J* = 8 Hz, 2H, CH₂–NH₂), 3.10–3.17 (m, 2H, CH₂–O), 3.64–3.70 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 3.91–3.97 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.11–4.16 (t, *J* = 8 Hz, 1H, Ar–CH–Ar), 6.49 (s, 2H, fumarate), 6.59–6.62 (d, *J* = 8 Hz, 1H, Ar–H), 6.72 (s, 1H, Ar–H), 7.04–7.23 (brm, 5H, Ar–H). ¹³C NMR (CD₃OD) δ 14.95, 19.38, 24.08, 29.96, 30.68, 36.63, 45.51, 48.71, 48.99, 50.7, 53.28, 69.62, 114.59, 115.91, 128.5, 129.98, 130.86, 136.85, 137.8, 138.75, 140.30, 160.58, 171.87. Anal. (C₂₀H₂₅NO·C₄H₄O₄) C, H, N.

3-Hydroxy-9-aminomethyl-9,10-dihydroanthracene hydrobromide (1g). The hydrobromide salt of **1e** was prepared by adding ethereal HBr to 3-methoxy-9-aminomethyl-9,10-dihydroanthracene in anhydrous Et₂O until no further precipitate formed. The suspension was filtered, and the filter cake was washed with anhydrous Et₂O. The white powder was recrystallized from EtOAc/2-PrOH to provide 3-methoxy-9-aminomethyl-9,10-dihydroanthracene hydrobromide as a white powder; mp 258–261 °C dec. A 1.0 M solution of BBr₃ in CH₂Cl₂ (1.0 mL, 0.960 mmol) was added under N₂ in a dropwise manner to 3-methoxy-9-aminomethyl-9,10-dihydroanthracene hydrobromide (0.100 g, 0.320 mmol) in CHCl₃ at –78 °C (dry ice/acetone). The suspension was allowed to warm to room temperature over 2 h and was then allowed to stir for 5 h. The suspension was cooled to –78 °C, anhydrous MeOH (7 mL) was added, and the suspension was allowed to warm to room temperature. The suspension was concentrated under reduced pressure to provide a white solid that was recrystallized from 2-PrOH/CHCl₃ to provide **1g** (0.430 g, 43%) as a white powder; mp 278–281 °C dec. ¹H NMR (DMSO-*d*₆) δ 2.88–2.90 (d, *J* = 6 Hz), 2H, CH₂–NH₂), 3.77–3.84 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.03–4.10 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.10–4.16 (t, *J* = 6 Hz, 1H, Ar–CH–Ar), 6.64–6.67 (d, *J* = 8 Hz, 1H, Ar–H), 6.77 (s, 1H, Ar–H), 7.17–7.39 (brm, 7H, Ar–H). Anal. (C₁₅H₁₅NO·HBr·0.25 H₂O) C, H, N.

3-*n*-Hexyl-6-methoxy-9-aminomethyl-9,10-dihydroanthracene fumarate (1h). Compound **1h** was prepared from **20h** in a manner analogous to that of **1f**. The resulting yellow oil was purified using medium pressure column chromatography (CH₂Cl₂/MeOH, 9:1) to provide **1h** (0.0580 g, 20%) as a white powder; mp 169–171 °C. ¹H NMR (DMSO-*d*₆) δ 0.85–0.86 (t, *J* = 6 Hz, 3H, CH₃), 1.27 (m, 6H, CH₂), 1.53–1.58 (m, 2H, CH₂), 2.79–2.84 (d, *J* = 7 Hz, 2H, CH₂–NH₂), 3.74 (s, 3H, OCH₃), 3.78–3.84 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.04–4.08 (d, *J* = 19 Hz, 1H, Ar–CH₂–Ar), 4.08–4.12 (t, *J* = 7 Hz, 1H, Ar–CH–Ar), 6.44 (s, 2H, fumarate), 6.79–6.82 (d, *J* = 8 Hz, 1H, Ar–H), 6.93 (s, 1H, Ar–H), 7.04–7.06 (d, *J* = 8 Hz, 1H, Ar–H), 7.14 (s, 1H, Ar–H), 7.25–7.30 (m, 2H, Ar–H). Anal. (C₂₂H₃₀NO·C₄H₄O₄) C, H, N.

2-(4-Bromophenyl)-1-aminoethane hydrochloride (3b). A 1.0 M solution of borane–THF complex (30.6 mL, 30.6 mmol) was added to 4-bromophenyl acetonitrile (2.00 g, 10.2 mmol) in anhydrous THF (10 mL). The solution was heated at reflux for 8 h. The solution was allowed to cool to room temperature, 6 M HCl (10 mL) was cautiously added, and the solution was heated at reflux for 30 min. The solution was allowed to cool to room temperature,

10% NaOH (45 mL) was added, and the suspension was extracted with CH_2Cl_2 (3×50 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide (1.50 g) of a colorless oil. The oil was dissolved in anhydrous Et_2O (50 mL), and ethereal HCl was added until no more precipitate formed. The suspension was filtered and washed with anhydrous Et_2O to provide a white solid that was recrystallized from 2-PrOH to provide **3b** (1.20 g, 58%) as white needles; mp 239–241 °C dec (lit⁴⁷ mp 240–243 °C). ^1H NMR (CD_3OD) δ 2.71–2.76 (m, 2H, CH_2), 2.93–2.98 (m, 2H, CH_2), 7.00–7.03 (d, J = 8 Hz, 2H, Ar-H), 7.27–7.30 (d, J = 8 Hz, 2H, Ar-H). ^{13}C NMR (CD_3OD) δ 34.43, 42.19, 132.37, 133.59.

2-(4-*n*-Hexylphenyl)-1-aminoethane hydrochloride (3d). Pd on charcoal (10%, 0.50 g) and concentrated sulfuric acid (0.300 g) were added to **26** (0.300 g, 1.40 mmol) in glacial acetic acid (5 mL). The mixture was hydrogenated (10 h) at 50 psi. The mixture was filtered through a celite pad, and the filter cake was washed with glacial acetic acid (15 mL). The filtrate was concentrated under reduced pressure and made basic to pH 10 with sat NaHCO_3 . The suspension was extracted with EtOAc (3×40 mL), and the organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide (0.210 g, 1.00 mmol) of a pale-yellow oil. The oil was dissolved in anhydrous Et_2O (25 mL), and a 1.0 M solution of HCl in Et_2O (1 mL) was added. The solution was cooled and filtered to provide a white powder. The powder was recrystallized from 2-PrOH/ Et_2O to provide **3d** (0.180 g, 53%) as white plates; mp 176–178 °C. (lit³¹ 175–177 °C). ^1H NMR ($\text{DMSO}-d_6$) δ 0.85–0.87 (t, J = 8 Hz, 3H, CH_3), 1.12–1.14 (s, 6H, CH_2), 1.61–1.63 (m, 2H, CH_2), 2.49–2.54 (t, J = 7.7 Hz, 2H, Ar- CH_2), 2.83–2.87 (m, 2H, CH_2), 2.95–2.99 (m, 2H, CH_2), 7.13 (s, 4H, Ar-H). ^{13}C NMR ($\text{DMSO}-d_6$) δ 14.33, 22.44, 28.71, 31.34, 31.48, 32.91, 35.13, 40.27, 128.84, 134.37, 141.02.

2-(4-Bromophenyl)-2-phenyl-1-aminoethane hydrochloride (4b). A 1.0 M solution of borane–THF complex (7.28 mL, 7.28 mmol) was added at room temperature to a well stirred solution of 2-(4-bromophenyl)-2-phenylacetonitrile (**27** 0.500 g, 1.82 mmol) in anhydrous THF (5 mL). The solution was then heated at reflux (5 h) and allowed to cool. A 6.0 M solution of HCl (7 mL) was cautiously added, and the suspension was heated at reflux (30 min). The suspension was allowed to cool, made basic with 10% NaOH (≈ 35 mL), and extracted with Et_2O (3×35 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide an oily solid. The solid was dissolved in anhydrous Et_2O (40 mL), and ethereal HCl was added. The white suspension was filtered and washed with anhydrous Et_2O (10 mL). The white solid was recrystallized from 2-PrOH to provide **4b** (0.290 g, 51%) as white crystals; mp 216–218 °C. ^1H NMR ($\text{DMSO}-d_6$) δ 3.44–3.58 (m, 2H, $\text{CH}_2\text{-NH}_2$), 4.37–4.42 (t, J = 8 Hz, 1H, CH), 7.23–7.53 (brn, 9H, Ar-H). Anal. ($\text{C}_{14}\text{H}_{14}\text{BrN}\cdot\text{HCl}$) C, H, N.

2-(4-*n*-Hexylphenyl)-2-phenyl-1-aminoethane hydrochloride (4d). A methanolic solution containing Raney nickel (≈ 0.500 g) was added to 2-(4-*n*-hexylphenyl)-2-phenylacetonitrile (**30**, 0.400 g, 1.44 mmol) in anhydrous MeOH (20 mL) and sat NH_3/MeOH solution (5 mL). The suspension was hydrogenated at 40 psi for 10 h. The suspension was filtered through a celite pad, and the filter cake was washed with anhydrous MeOH (25 mL). The filtrate was concentrated under reduced pressure to provide a colorless oil. The oil was dissolved in anhydrous Et_2O (35 mL), and ethereal HCl was added until no further precipitate formed. The white suspension was filtered and washed with anhydrous Et_2O (10 mL). The white solid was recrystallized from 2-PrOH/ Et_2O to provide **4d** (0.200 g, 44%) as white crystals; mp 174–175 °C. ^1H NMR (CD_3OD) δ 0.65–0.69 (t, J = 8 Hz, 2H, CH_3), 1.09 (s, 6H, CH_2), 1.32–1.39 (m, 2H, CH_2), 2.34–2.39 (t, J = 7.7 Hz, 2H, CH_2), 3.38–3.41 (d, J = 7.8 Hz, 2H, CH_2), 4.02–4.07 (t, J = 8.25 Hz, 1H, CH), 6.95–7.17 (brn, 9H, Ar-H). ^{13}C NMR ($\text{DMSO}-d_6$) δ 14.51, 20.41, 30.48, 33.17, 33.21, 37.02, 45.08, 50.87, 129.33, 129.42, 130.68, 130.73. Anal. ($\text{C}_{20}\text{H}_{27}\text{N}\cdot\text{HCl}$) C, H, N.

1-Bromo-2-[(methoxymethoxy)methyl]benzene (5). Chloromethylmethyl ether (1.61 g, 20.0 mmol) was added in a dropwise

manner to a well-stirred solution of 2-bromobenzyl alcohol (3.00 g, 16.0 mmol) in *N,N*-diisopropylethylamine (10 mL) at 0 °C under N_2 . The yellow solution was allowed to stir at 0 °C (2 h), allowed to warm to room temperature, and stirred (5 h). The solvent was removed under reduced pressure to provide a yellow oil. The oil was dissolved in CHCl_3 (30 mL) and washed with water (3×75 mL). The organic extract was dried (MgSO_4) and concentrated under reduced pressure to provide a pale-yellow oil that was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **5** (2.79 g, 75%) as a colorless oil. ^1H NMR (CDCl_3) δ 3.49 (s, 3H, CH_3), 4.65 (s, 2H, CH_2), 4.75 (s, 2H, CH_2), 7.16–7.57 (brn, 4H, Ar-H). Compound **5** was used without further characterization in the preparation of **6**.

1-[1-(4-Bromophenyl)-2-nitroethyl]-2-[(methoxymethoxy)methyl]benzene (6). A crystal of I_2 was added to clean, dry magnesium turnings (0.160 g, 6.58 mmol) in anhydrous THF (10 mL). 1-Bromo-2-[(methoxymethoxy)methyl]benzene (**5**, 1.58 g, 6.58 mmol) was slowly added (maintaining a gentle reflux) to the THF/Mg suspension, and the mixture was heated at reflux (≈ 45 min or until most of the Mg was dissolved). The suspension was allowed to cool to room temperature, the solvent was decanted from the unreacted Mg turnings and slowly added in a dropwise manner (not allowing the temperature to rise above 10 °C) to an ice-cold well-stirred solution of *trans*-2-(4-bromophenyl)-1-nitroethene (1.50 g, 6.58 mmol) in anhydrous THF (15 mL). After the addition was complete, the reaction was allowed to warm to room temperature (1 h) and stirring was continued (10 h). HCl (1.0 M, 15 mL) was added, and the suspension was concentrated under reduced pressure. Water (25 mL) was added, and the yellow suspension was extracted with EtOAc (3×20 mL) and washed with sat NaHCO_3 (40 mL) and brine (40 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide a viscous yellow oil. The resulting oil was purified by medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **6** (1.00 g, 40%) as a viscous yellow oil. ^1H NMR (CDCl_3): δ 3.45 (s, 3H, OCH_3), 4.56–4.98 (brn, 6H, CH_2), 5.29–5.35 (t, J = 8 Hz, 1H, Ar-CH-Ar), 7.1–7.46 (brn, 9H, Ar-H). ^{13}C NMR (CDCl_3) δ 44.07, 56.25, 68.06, 79.35, 96.32, 127.68, 128.39, 129.46, 130.05, 131.55, 132.66. IR (film) 1556, 1376 cm^{-1} . Compound **6** was used in the preparation of **7**.

{2-[1-(4-Bromophenyl)-2-nitroethyl]phenyl}methanol (7). Concentrated HCl (4 drops) was added to 1-[1-(4-bromophenyl)-2-nitroethyl]-2-[(methoxymethoxy)methyl]benzene (**6**, 1.00 g, 2.63 mmol) in MeOH (15 mL). The reaction mixture was heated in an oil bath at 65 °C (5 h). The solution was allowed to cool to room temperature and concentrated under reduced pressure to provide a viscous yellow oil. The oil was dissolved in EtOAc (20 mL), the suspension was made basic with sat NaHCO_3 (≈ 50 mL), and the mixture was extracted with EtOAc (3×20 mL). The organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide a viscous yellow oil that was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **7** (0.800 g, 90%) as a viscous yellow oil. ^1H NMR (CDCl_3) δ 4.64–4.92 (m, 2H, Ar- $\text{CH}_2\text{-OH}$), 4.93–5.06 (m, 2H, $\text{CH}_2\text{-NO}_2$), 5.3–5.36 (t, J = 8 Hz, 1H, Ar-CH-Ar), 7.1–7.4 (brn, 8H, Ar-H). IR (film) 3384, 1550, 1375 cm^{-1} .

3-Bromo-9-nitromethyl-9,10-dihydroanthracene (8). PPA (5 mL) was added to {2-[1-(4-bromophenyl)-2-nitroethyl]phenyl}methanol (**7**, 1.02 g, 3.04 mmol), and the viscous mixture was stirred by hand and heated in an oil bath at 65 °C (30 min). After the reaction was complete, ice (40.0 g) was added to the white/brown semisolid and the solution was made basic to pH 12 with sat NaHCO_3 solution. The suspension was extracted with EtOAc (3×25 mL) and the organic extracts were combined, dried (MgSO_4), and concentrated under reduced pressure to provide a brown semisolid (0.540 g). The crude solid was then recrystallized from methanol to provide **8** (0.480 g, 49%) as pale-yellow crystals; mp 113–114 °C. ^1H NMR (CDCl_3): δ 3.80–3.95 (d, J = 19 Hz, 1H, CH_2), 4.07–4.13 (d, J = 19 Hz, 1H, Ar- $\text{CH}_2\text{-Ar}$), 4.37–4.49 (m, 2H, $\text{CH}_2\text{-NO}_2$), 4.76–4.82 (t, J = 9 Hz, 1H, CH), 7.15–7.39 (brn, 7H, Ar-H). ^{13}C NMR (CDCl_3) δ 35.22, 45.5, 80.15, 122.27,

127.85, 128.56, 128.66, 128.85, 130.24, 130.61, 131.75, 133.91, 134.28, 136.05, 139.17. IR (KBr) 1537, 1382, cm⁻¹.

4-Bromo-2-(bromomethyl)benzonitrile (9). NBS (3.49 g, 19.6 mmol) was added to 4-bromo-2-methylbenzonitrile (3.50 g, 17.9 mmol) in CCl₄ (25 mL) under N₂. The reaction was slowly warmed with an IR lamp and heated at reflux (6 h). The suspension was cooled and filtered and the filtrate was concentrated under reduced pressure to provide an oily solid. The oily solid was purified using medium pressure column chromatography (petroleum ether/acetone 9:1) to provide a white solid that was recrystallized (toluene/petroleum ether) to provide **9** (3.45 g, 70%) as white needles; mp 88–91 °C. ¹H NMR (CDCl₃) δ 4.55 (s, 2H, CH₂-Br), 7.54–7.58 (m, 2H, Ar-H), 7.73 (s, 1H, Ar-H). ¹³C NMR (CDCl₃) δ 28.78, 128.72, 132.90, 133.81, 134.26, 134.78, 142.67. The product was used in the preparation of **10**.

2-Benzyl-4-bromobenzonitrile (10). 4-Bromo-2-(bromomethyl)benzonitrile (**9**, 3.25 g, 11.82 mmol) was added under N₂ to AlCl₃ (3.14 g, 23.6 mmol) in anhydrous benzene (30 mL) at 0 °C. The reaction mixture was allowed to warm to room temperature and heated at reflux (45 min). The reaction was allowed to cool, poured onto ice (50.0 g), and made acidic to pH 2 with 5% HCl. The suspension was extracted with CH₂Cl₂ (3 × 75 mL) and the combined extracts were washed with water and brine, dried (MgSO₄), and concentrated under reduced pressure to provide a white solid. The white solid was recrystallized from toluene/petroleum ether to provide **10** (3.10 g, 96%) as white crystals; mp 73–75 °C. ¹H NMR (CDCl₃) δ 4.13 (s, 2H, Ar-CH₂-Ar), 7.07–7.50 (brm, 8H, Ar-H). ¹³C NMR (CDCl₃) δ 40.56, 127.63, 129.49, 129.55, 130.88, 133.82, 134.55. Compound **10** was used without further characterization in the preparation of **11**.

2-Benzyl-4-bromobenzoic acid (11). 2-Benzyl-4-bromobenzonitrile (**10**, 0.90 g, 3.31 mmol) was added to KOH (1.15 g, 24.2 mmol) in ethylene glycol (7 mL) and water (0.5 mL). The solution was heated at reflux (3 h), allowed to cool to room temperature, and made acidic to pH 2 with 5% HCl. The suspension was extracted with CHCl₃ (3 × 50 mL), and the extracts were washed with water and brine, dried (MgSO₄), and concentrated under reduced pressure to provide a white solid. The solid was recrystallized from formic acid/acetic acid to provide **11** (0.950 g, 100%) as white crystals; mp 131–134 °C. ¹H NMR (DMSO-*d*₆) δ 4.36 (s, 2H, Ar-CH₂-Ar), 6.67 (s, 1H, Ar-H), 7.01–7.04 (d, *J* = 8 Hz, 1H, Ar-H), 7.16–7.78 (brm, 6H, Ar-H).

2-Benzyl-4-bromobenzyl alcohol (12). Compound **12** was prepared from **11** in a manner analogous to that of **21**. The resulting oil (1.01 g, 96%) was used in the next step without further purification.

2-Benzyl-4-bromobenzaldehyde (13). Compound **13** was prepared from **12** in a manner analogous to that of **19d**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **13** (0.750 g, 75%) as a colorless oil. ¹H NMR (CDCl₃) δ 4.27 (s, 2H, Ar-CH₂-Ar), 7.02–7.29 (brm, 7H, Ar-H), 7.69–7.74 (d, *J* = 6 Hz, 1H, Ar-H), 10.11 (s, 1H, COH).

2-Benzyl-4-(3-phenylpropyl)benzaldehyde (14). A 0.5 M solution of 9-BBN in THF (8 mL, 4.00 mmol) was added under N₂ in a dropwise manner to a solution of allylbenzene (0.470 g, 4.01 mmol) in anhydrous THF (2.5 mL) at 0 °C. The mixture was then allowed to stir for 12 h at room temperature. 2-Benzyl-4-bromobenzaldehyde (**13**, 1.00 g, 3.34 mmol) in THF (12 mL), PdCl₂(dppf) (0.080 g, 0.100 mmol), and NaOH (3 M, 3.34 mL) were then added to the flask containing the 9-phenylpropyl-9-BBN. The mixture was heated at reflux (12 h), allowed to cool to room temperature, and water (20 mL) was added. The suspension was extracted with EtOAc (3 × 50 mL), and the combined extracts were washed with water and brine, dried (MgSO₄), and concentrated under reduced pressure. The resulting brown oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **14** (0.700 g, 66%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.90–2.00m (m, 2H, CH₂), 2.60–2.68 (m, 4H, Ar-CH₂), 4.40 (s, 2H, Ar-CH₂-Ar), 7.06–7.30 (brm, 12H, Ar-H), 7.76–7.79 (d, *J* = 8 Hz, 1H, Ar-H), 10.17 (s, 1H, COH). ¹³C NMR (CDCl₃) δ 33.00, 35.90, 36.03,

38.62, 126.50, 126.80, 127.70, 128.97, 129.13, 129.29, 130.23, 132.49, 132.98, 141.13, 142.36, 143.60, 149.73, 192.55.

2-Amino-1-[2-benzyl-4-(3-*n*-phenylpropyl)phenyl]-1-ethanol oxalate (15). Compound **15** was prepared from **14** in a manner analogous to that of **20d**. The oxalate salt was recrystallized from 2-ProH to provide **15** (0.630 g, 64%) as a white powder; mp 168–170 °C. ¹H NMR (DMSO-*d*₆) δ 1.78–1.88 (m, 2H, CH₂), 2.45–2.57 (m, 4H, CH₂-Ar), 2.70–2.79 (m, 2H, CH₂-NH₂), 3.92–3.97 (d, *J* = 16 Hz, 1H, Ar-CH₂-Ar), 4.02–4.07 (d, *J* = 16 Hz, 1H, Ar-CH₂-Ar), 5.05–5.08 (d, *J* = 9 Hz, CH-OH), 6.96 (s, 1H, Ar-H), 7.15–7.53 (brm, 12H, Ar-H). Anal. (C₂₄H₂₇NO·C₂H₂O₄) C, H, N.

2-(4-*n*-Hexylphenyl)-4,4-dimethyl-2-oxazoline (16d). A solution of 4-*n*-hexylbenzoyl chloride (3.00 g, 13.3 mmol) in CH₂Cl₂ (6 mL) was added under N₂ to 2-amino-2-methyl-1-propanol (2.49 g, 27.9 mmol) in CH₂Cl₂ (6 mL) at such a rate as to maintain a temperature of 0 °C. The suspension was allowed to stir for 4 h and was filtered. The filter cake was washed with CH₂Cl₂ (2 × 20 mL), and the filtrate was washed with 3N HCl (100 mL) and water (100 mL). The solvent was removed under reduced pressure to provide (3.60 g, 97%) a yellow oil. Thionyl chloride (1.83 g, 15.31 mmol) was added slowly to the crude 4-*n*-hexyl-*N*-(2-hydroxy-1,1-dimethylethyl) benzamide (3.60 g, 13.0 mmol) in anhydrous toluene (25 mL). The solution was stirred at room temperature (10 h), poured into water (30 mL), made basic to pH 10 with sat NaHCO₃, and extracted with EtOAc (3 × 40 mL). The extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a pale-orange oil. The oil was purified by Kuhgelrohr bulb to bulb distillation (bp 141 °C at 0.10 mmHg) to provide **16d** (3.33 g, 98%) as a colorless oil. ¹H NMR (CDCl₃) δ 0.85–0.89 (t, *J* = 7 Hz, 3H, CH₃), 1.28 (s, 6H, CH₂), 1.37 (s, 6H, CH₃), 1.53–1.62 (m, 2H, CH₂), 2.6–2.65 (t, *J* = 7 Hz, 2H, Ar-CH₂), 4.09 (s, 2H, CH₂-O), 7.19–7.22 (d, *J* = 8 Hz, 2H, Ar-H), 7.83 (d, *J* = 8 Hz, 2H, Ar-H). ¹³C NMR (CDCl₃) δ 14.64, 23.14, 28.99, 29.43, 31.76, 32.23, 36.48, 79.59, 128.74, 128.92, 147.09. IR (film) 1655 cm⁻¹.

5-*n*-Hexyl-3-phenyl-1,3-dihydro-1-isobenzofuranone (17d). A well-stirred solution of 2-(4-*n*-hexylphenyl)-4,4-dimethyl-2-oxazoline (**16d**, 1.00 g, 3.85 mmol) in anhydrous THF (5 mL) was cooled to –78 °C (dry ice/acetone) under N₂. A 2.5 M solution of *n*-butyl lithium in cyclohexane (1.77 mL, 4.43 mmol) was added slowly to the solution so as to maintain the temperature at –78 °C. The solution was allowed to warm to room temperature and stirred (1 h). The red solution was then cooled to 0 °C, and a solution of benzaldehyde (0.410 g, 3.85 mmol) in anhydrous THF (2 mL) was added over 30 min. The reaction mixture was allowed to stir for 5 h at room temperature, and H₂O (20 mL) was added. The mixture was extracted with EtOAc (3 × 30 mL). The combined fractions were dried (MgSO₄) and concentrated under reduced pressure to provide a yellow oil. HCl (5%, 25 mL) was added to the oil, and the suspension was heated at reflux (10 h). The suspension was allowed to cool and then extracted with EtOAc (3 × 40 mL). The combined extracts were dried (MgSO₄) and concentrated under reduced pressure to provide an orange oil that was purified by medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **17d** (0.910 g, 80%) as a colorless oil that solidified on standing. The solid was recrystallized from EtOAc/petroleum ether; mp 69–70 °C. ¹H NMR (CDCl₃) δ 0.85 (s, 3H, CH₃), 1.28 (s, 6H, CH₂), 1.53–1.62 (m, 2H, CH₂), 2.6–2.65 (s, 2H, Ar-CH₂), 6.35 (s, 1H, Ar-CH-Ar), 7.26–7.86 (brm, 8H, Ar-H). IR (KBr) 1743 cm⁻¹.

3-(3-Methoxyphenyl)-1,3-dihydro-1-isobenzofuranone (17e). Compound **17e** was prepared from 3-methoxybenzaldehyde and 2-phenyl-4,4-dimethyl-2-oxazoline in a manner analogous to **17d**. The resulting yellow solid was recrystallized from EtOH/MeOH to provide **17e** (5.60 g, 81%) as yellow needles; mp 112–114 °C. ¹H NMR (CDCl₃) δ 3.77 (s, 3H, OCH₃), 6.37 (s, 1H, Ar-CH-Ar), 6.78–6.91 (m, 3H, Ar-H), 7.27–7.96 (brm, 5H, Ar-H). ¹³C NMR (CDCl₃) δ 54.89, 82.08, 111.98, 114.20, 118.65, 122.41, 125.02, 125.20, 128.94, 129.63, 133.90, 137.50, 149.16, 159.57, 170.06.

3-[3-(*n*-Pentyloxy)phenyl]-1,3-dihydro-1-isobenzofuranone (17f). Compound **17f** was prepared from **21** (3-*n*-pentyloxybenzaldehyde) and 2-phenyl-4,4-dimethyl-2-oxazoline in a manner analogous to **17d**. The resulting yellow solid was recrystallized from toluene/petroleum ether to provide **17f** (4.78 g, 55%) as yellow needles; mp 94–96 °C. ¹H NMR (CDCl₃) δ 0.89–0.94 (t, *J* = 7 Hz, 3H, CH₃), 1.3–1.46 (m, 4H, CH₂), 1.70–1.79 (m, 2H, CH₂), 3.88–3.93 (t, *J* = 7 Hz, 3H, CH₂-O), 6.36 (s, 1H, Ar-CH-Ar), 6.77 (s, 1H, Ar-H), 6.85–6.90 (m, 2H, Ar-H) 7.25–7.67 (brm, 4H, Ar-H), 7.94–7.96 (d, *J* = 8 Hz, 1H, Ar-H). ¹³C NMR (CDCl₃) δ 14.56, 23.0, 28.71, 29.45, 68.63, 83.15, 113.55, 115.65, 119.46, 123.42, 126.04, 126.19, 129.91, 130.57, 134.88, 138.42, 150.23, 160.16.

5-*n*-Hexyl-3-(3-methoxyphenyl)-1,3-dihydro-1-isobenzofuranone (17h). Compound **17h** was prepared from **16d** (2-(4-*n*-hexylphenyl)-4,4-dimethyl-2-oxazoline) and 3-methoxybenzaldehyde in a manner analogous to that of **17d**. The resulting orange oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **17h** (4.82 g, 77%) as a yellow oil. ¹H NMR (CDCl₃) δ 0.83–0.87 (t, *J* = 6 Hz, 3H, CH₃), 1.28 (m, 6H, CH₂), 1.57–1.60 (m, 2H, CH₂), 2.64–2.69 (t, *J* = 8 Hz, 2H, CH₂-Ar), 3.77 (s, 3H, OCH₃), 6.31 (s, 1H, Ar-CH-Ar), 6.79–6.90 (m, 3H, Ar-H), 7.12 (s, 1H, Ar-H), 7.27–7.36 (m, 2H, Ar-H), 7.82–7.85 (d, *J* = 8 Hz, 1H, Ar-H). ¹³C NMR (CDCl₃) δ 14.59, 23.08, 29.44, 31.74, 32.12, 36.93, 55.88, 82.91, 112.99, 115.14, 119.73, 122.99, 123.68, 126.00, 130.52, 130.58, 138.78, 150.69, 151.24, 160.62. IR (film) 1772 cm⁻¹.

2-Benzyl-4-*n*-hexylbenzoic acid (18d). Five drops of HClO₄ (70% in water), 10% Pd/C (0.100 g), and 5-*n*-hexyl-3-phenyl-1,3-dihydro-1-isobenzofuranone **17d** (0.400 g, 1.36 mmol) was hydrogenated in 2-PrOH (11 mL) at 55 psi for 12 h. The suspension was filtered through a celite pad and concentrated under reduced pressure. The resulting oil was dissolved in CHCl₃ (50 mL) and extracted with 10% NaOH (40 mL). The aqueous layer was made acidic to pH 3 with 5% HCl and extracted with CH₂Cl₂ (3 × 50 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a white solid. The solid was recrystallized from formic acid/acetic acid to provide **18d** (0.300 g, 74%) as white needles; mp 67–68 °C. ¹H NMR (CDCl₃) δ 0.84–0.89 (t, *J* = 7 Hz, 2H, CH₃), 1.27 (brs, 6H, CH₂), 1.53–1.58 (m, 2H, CH₂), 2.56–2.61 (t, *J* = 6 Hz, 2H, CH₂), 4.43 (s, 2H, Ar-CH₂-Ar), 7.03–7.28 (brm, 7H, Ar-H), 7.98–8.01 (d, *J* = 8 Hz, 1H, Ar-H). ¹³C NMR (CDCl₃) δ 14.65, 23.15, 29.47, 31.51, 32.20, 36.43, 40.23, 126.42, 127.04, 128.84, 129.52, 132.56, 132.65, 149.22, 173.23. IR (KBr) 2924, 1687 cm⁻¹.

2-(3-Methoxybenzyl)benzoic acid (18e). Compound **18e** was prepared from **17e** in a manner analogous to **18d**. The resulting white solid was recrystallized from formic acid/acetic acid to provide **18e** (1.81 g, 89%) as white needles; mp 95–96 °C. ¹H NMR (CDCl₃) δ 3.77 (s, 3H, OCH₃), 4.46 (s, 2H, Ar-CH₂-Ar), 6.75–6.77 (d, *J* = 7 Hz, 1H, Ar-H), 6.8 (s, 1H, Ar-H), 7.18–7.5 (brm, 5H, Ar-H), 8.08–8.10 (d, *J* = 7.8 Hz, 1H, Ar-H). ¹³C NMR (CDCl₃) 40.19, 55.67, 111.92, 115.48, 122.13, 126.97, 129.87, 132.29, 133.62, 142.89, 143.89, 173.79.

2-[3-(*n*-Pentyloxy)benzyl]benzoic acid (18f). Compound **18f** was prepared from **17f** in a manner analogous to that of **18d**. The resulting white solid was recrystallized from formic acid/acetic acid to provide **18f** (4.18 g, 96%) as white needles; mp 89–91 °C. ¹H NMR (DMSO-*d*₆) δ 0.85–0.89 (t, *J* = 6 Hz, 3H, CH₃), 1.27–1.33 (m, 4H, CH₂), 1.61–1.68 (m, 2H, CH₂), 3.84–3.88 (t, *J* = 6 Hz, 2H, CH₂-O), 4.30 (s, 2H, Ar-CH₂-Ar), 6.69 (m, 2H, Ar-H), 6.71 (s, 1H, Ar-H), 7.11–7.48 (brm, 4H, Ar-H), 7.79–7.82 (d, *J* = 8 Hz, 1H, Ar-H). ¹³C NMR (DMSO-*d*₆) 14.26, 22.26, 28.09, 28.76, 38.74, 67.53, 111.83, 115.44, 121.18, 126.65, 129.59, 130.57, 131.06, 131.70, 132.07, 141.80, 143.03, 159.03, 169.22.

4-*n*-Hexyl-2-(3-methoxybenzyl)benzoic acid (18h). Compound **18h** was prepared from **17h** in a manner analogous to that of **18d**. The resulting yellow semisolid was recrystallized from formic acid/acetic acid to provide **18h** (2.21 g, 84%) as a white powder; mp 58–60 °C. ¹H NMR (CDCl₃) δ 0.86–0.91 (t, *J* = 6 Hz, 3H, CH₃), 1.29 (m, 6H, CH₂), 1.55–1.62 (m, 2H, CH₂), 2.58–2.63 (t, *J* = 8 Hz, 2H, CH₂-Ar), 3.76 (s, 3H, OCH₃), 4.43 (s, 2H, Ar-CH₂-Ar),

6.73–6.78 (m, 3H, Ar-H) 7.05–7.21 (brm, 3H, Ar-H), 7.99–8.0 (d, *J* = 8 Hz, 1H, Ar-H). ¹³C NMR (CDCl₃) δ 14.64, 23.14, 29.77, 31.50, 32.21, 36.43, 40.22, 55.63, 111.83, 115.32, 122.01, 126.23, 127.06, 129.75, 132.55, 132.60, 143.16, 143.84, 149.23, 160.00, 173.44.

2-Benzyl-4-*n*-hexylbenzaldehyde (19d). A solution of 2-benzyl-4-*n*-hexylbenzyl alcohol (**21**, 0.400 g, 1.42 mmol) in anhydrous CH₂Cl₂ (5 mL) was added over 30 min at room temperature to a well-stirred suspension of PCC (0.460 g, 2.13 mmol) and celite (1.0 g in 50 mL CH₂Cl₂). The solution was allowed to stir at room temperature for 2 h, anhydrous Et₂O (25 mL) was added, and the dark-brown suspension was filtered through a Florisil column. The solution was concentrated under reduced pressure to provide **19d** (0.320 g, 80%) as a colorless oil. The product was used without further purification. ¹H NMR (CDCl₃) δ 0.85–0.87 (t, *J* = 7 Hz, 2H, CH₃), 1.28 (brs, 6H, CH₂), 1.55–1.60 (m, 2H, CH₂), 2.60–2.65 (t, *J* = 8 Hz, 2H, CH₂), 4.14 (s, 2H, Ar-CH₂-Ar), 7.07–7.29 (brm, 7H, Ar-H), 7.75–7.78 (d, *J* = 8 Hz, 1H, Ar-H), 10.17 (s, 1H, COH). ¹³C NMR (CDCl₃) δ 14.65, 23.15, 29.50, 31.52, 32.21, 36.66, 38.65, 126.76, 127.68, 129.08, 129.28, 132.47, 132.93, 140.85, 143.48, 150.55, 192.59. IR (film) 1693 cm⁻¹.

2-(3-Methoxybenzyl)benzaldehyde (19e). Compound **19e** was prepared from **23** in a manner analogous to that of **19d**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **19e** (0.490 g, 98%) as a pale-yellow oil. ¹H NMR (CDCl₃) δ 3.75 (s, 3H, OCH₃), 4.42 (s, 2H, Ar-CH₂-Ar), 6.68 (s, 1H, Ar-H), 6.72–6.75 (d, *J* = 8.2 Hz, 1H, Ar-H), 7.17–7.53 (brm, 5H, Ar-H), 7.84–7.85 (d, *J* = 3 Hz, 1H, Ar-H), 10.24 (s, 1H, COH). ¹³C NMR (CDCl₃) 38.59, 55.69, 111.96, 115.34, 121.77, 127.60, 130.10, 132.21, 132.56, 134.50, 192.95. IR (film) 1699 cm⁻¹.

2-[3-(*n*-Pentyloxy)benzyl]benzaldehyde (19f). Compound **19f** was prepared from **24** in a manner analogous to that of **19d**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **19f** (3.56 g, 100%) as a pale-yellow oil. ¹H NMR (CDCl₃) δ 0.85–0.93 (t, *J* = 7 Hz, 3H, CH₃), 1.32–1.42 (m, 4H, CH₂), 1.69–1.76 (m, 2H, CH₂), 3.86–3.90 (t, *J* = 7 Hz, 2H, CH₂-O), 4.40 (s, 2H, Ar-CH₂-Ar), 6.68–6.73 (m, 3H, Ar-H), 7.14–7.54 (brm, 4H, Ar-H), 7.83–7.87 (d, *J* = 8 Hz, 1H, Ar-H), 10.24 (s, 1H, COH).

4-*n*-Hexyl-2-(3-methoxybenzyl)benzaldehyde (19h). Compound **19h** was prepared from **25** in manner analogous to that of **19d**. The resulting brown oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **19h** (1.98 g, 92%) as a pale-yellow oil. ¹H NMR (CDCl₃) δ 0.85–0.89 (t, *J* = 6 Hz, 3H, CH₃), 1.26–1.29 (m, 6H, CH₂), 1.58–1.63 (m, 2H, CH₂), 2.59–2.65 (t, *J* = 8 Hz, 2H, CH₂-Ar), 3.75 (s, 3H, OCH₃), 4.39 (s, 2H, Ar-CH₂-Ar), 6.68–6.74 (m, 3H, Ar-H), 7.07–7.23 (m, 3H, Ar-H), 7.75–7.78 (d, *J* = 8 Hz, 1H, Ar-H), 10.17 (s, 1H, COH). ¹³C NMR (CDCl₃) δ 14.62, 23.12, 29.48, 31.50, 32.20, 36.64, 38.62, 55.66, 111.89, 115.25, 121.70, 127.69, 130.03, 132.44, 132.87, 142.68, 143.27, 150.41, 160.0, 192.54. IR (film) 1700 cm⁻¹.

2-Amino-1-(2-benzyl-4-*n*-hexylphenyl)-1-ethanol oxalate (20d). Trimethylsilyl cyanide (0.270 g, 2.78 mmol) was added to a suspension of 2-benzyl-4-*n*-hexylbenzaldehyde (**19d**, 0.650 g, 2.32 mmol) and ZnI₂ (catalytic amount) in anhydrous CH₂Cl₂ (3 mL). The solution was allowed to stir at room temperature (3 h) and heated at reflux (1 h). The solution was allowed to cool to room temperature and concentrated under reduced pressure to give a pale-yellow oil. The oil in anhydrous THF (5 mL) was added under N₂ to a suspension of LiAlH₄ (0.260 g, 6.85 mmol) in anhydrous THF (10 mL) at 0 °C. The solution was warmed to room temperature and heated at reflux (5 h). The solution was allowed to cool to room temperature, and water, (0.25 mL), 10% NaOH (0.25 mL), and celite (1.5 g) were added. The suspension was filtered through a sintered glass filter, and the filter cake was washed with CH₂Cl₂ (75 mL). The filtrate was dried (MgSO₄) and concentrated under reduced pressure to provide (0.460 g) a colorless oil. The oil was dissolved in anhydrous acetone (20 mL), and oxalic acid (0.130 g, 1.38 mmol) was added. The solution was heated until the solid dissolved, and the solution was cooled and filtered to provide **20d**

(0.420 g, 45%) as white crystals; mp 164–166 °C. ¹H NMR (DMSO-*d*₆) δ 0.85–0.87 (s, 2H, CH₃), 1.28 (brs, 6H, CH₂), 1.55–1.60 (brs, 2H, CH₂), 2.48–2.53 (t, *J* = 6 Hz, 2H, CH₃), 2.69–2.78 (m, 2H, CH₂–NH₂), 3.91–3.96 (d, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 4.00–4.06 (d, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 5.03–5.06 (d, *J* = 8.5 Hz, 1H, CH–OH), 6.97–7.44 (brm, 8H, Ar–H). ¹³C NMR (DMSO-*d*₆) δ 14.67, 23.20, 29.60, 31.93, 32.27, 36.14, 38.79, 46.38, 67.06, 126.55, 126.91, 127.67, 129.01, 129.46, 131.11, 137.95, 136.09, 141.01, 143.45.

2-Amino-1-[2-(3-methoxybenzyl)phenyl]-1-ethanol oxalate (20e). Compound **20e** was prepared from **19e** in a manner analogous to **20d**. The oxalate salt was prepared and recrystallized from 2-PrOH to provide **20e** (0.130 g, 33%) as a white powder; mp 159–161 °C. ¹H NMR (CD₃OD) δ 2.54–2.62 (m, 2H, CH₂–NH₂), 3.51 (s, 3H, OCH₃), 3.86 (s, 2H, Ar–CH₂–Ar), 4.93–4.98 (d, *J* = 9 Hz, 1H, Ar–CH–OH), 6.47–6.54 (m, 2H, Ar–H), 6.94–7.10 (brm, 5H, Ar–H), 7.38–7.40 (m, 1H, Ar–H). ¹³C NMR (CD₃OD) δ 39.65, 47.19, 56.11, 67.91, 113.02, 116.15, 122.61, 127.99, 128.75, 129.77, 131.13, 132.50, 139.18, 141.31, 144.10, 166.95.

2-Amino-1-[2-(3-*n*-pentyloxy)benzyl]phenyl]-1-ethanol oxalate (20f). Compound **20f** was prepared from **19f** in a manner analogous to that of **20d**. The oxalate salt was prepared and recrystallized from 2-PrOH to provide **20f** (2.68 g, 51%) as a white powder; mp 140–142 °C. ¹H NMR (DMSO-*d*₆) δ 0.85–0.90 (t, *J* = 7 Hz, 3H, CH₃), 1.13–1.18 (m, 2H, CH₂), 1.28–1.34 (m, 2H, CH₂), 2.7–2.84 (m, 2H, CH₂–NH₂), 3.83–3.92 (t, *J* = 7 Hz, 2H, CH₂–O), 3.93–3.98 (d, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 4.02–4.07 (s, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 5.2–5.23 (d, *J* = 8 Hz, 1H, CH–OH), 6.66–6.78 (m, 3H, Ar–H), 7.14–7.35 (brm, 4H, Ar–H), 7.53–7.67 (d, *J* = 8 Hz, 1H, Ar–H).

2-Amino-1-[4-*n*-hexyl-2-(3-methoxybenzyl)phenyl]-1-ethanol fumarate (20h). Compound **20h** was prepared from **19h** in a manner analogous to that of **20d**. The fumarate salt was recrystallized from EtOAc/2-PrOH to provide **20h** (0.510 g, 46%) as a white powder; mp 162–164 °C. ¹H NMR (DMSO-*d*₆) δ 0.81–0.85 (t, *J* = 6 Hz, 3H, CH₃), 1.24 (m, 6H, CH₂), 1.49–1.53 (m, 2H, CH₂), 2.64–2.83 (m, 2H, CH₂–NH₂), 3.69 (s, 3H, OCH₃), 3.86–3.91 (d, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 3.98–4.03 (d, *J* = 16 Hz, 1H, Ar–CH₂–Ar), 5.05–5.08 (d, *J* = 10 Hz, 1H, CH–OH), 6.46 (s, 2H, fumarate), 6.72–6.74 (m, 3H, Ar–H), 6.96 (s, 1H, Ar–H), 7.06–7.19 (brm, 2H, Ar–H), 7.41–7.43 (d, *J* = 8 Hz, 1H, Ar–H). ¹³C NMR (DMSO-*d*₆) δ 14.31, 22.43, 28.60, 31.25, 31.46, 35.10, 37.46, 45.97, 55.22, 66.21, 111.59, 114.80, 121.23, 126.54, 126.87, 129.66, 130.54, 135.68, 137.21, 138.04, 141.82, 142.62, 159.66, 168.84.

3-*n*-Pentyloxybenzaldehyde (21). KOH (3.25 g, 49.1 mmol) was added to 3-hydroxybenzaldehyde (5.00 g, 40.9 mmol) in absolute EtOH (125 mL). The mixture was allowed to stir for 30 min at room temperature, and 1-bromopentane (6.80 g, 45.0 mmol) was added. The reaction mixture was heated at reflux (12 h), the suspension was allowed to cool to room temperature, water (75 mL) was added, and the solution was extracted with Et₂O (3 × 75 mL). The combined extracts were washed with water and brine, dried (MgSO₄), and concentrated under reduced pressure to provide a pale-orange oil. The oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9:1) to provide **21** (5.82 g, 74%) as an orange oil. ¹H NMR (CDCl₃) δ 0.91–0.96 (t, *J* = 7 Hz, 3H, CH₃), 1.31–1.48 (m, 4H, CH₂), 1.17–1.85 (m, 2H, CH₂), 3.98–4.03 (t, *J* = 6 Hz, 2H, CH₂–O), 7.15–7.17 (m, 1H, Ar–H), 7.37–7.44 (brm, 3H, Ar–H), 9.96 (s, 1H, COH). ¹³C NMR (CDCl₃) δ 14.56, 22.98, 28.71, 29.38, 68.86, 113.35, 122.50, 123.82, 130.53, 138.34, 159.98, 192.75.

2-Benzyl-4-*n*-hexylbenzyl alcohol (22). A 1.0 M solution of borane–THF complex (8 mL, 8 mmol) was added under N₂ to a well stirred solution of 2-benzyl-4-*n*-hexylbenzoic acid (**18d**, 0.600 g, 2.00 mmol) at 0 °C. The solution was heated at reflux (5 h) and allowed to cool. HCl 6.0 M (5 mL) was added cautiously, and the mixture was again heated at reflux (30 min). The solution was allowed to cool to room temperature, made basic with 15% NaOH (≈ 30 mL), and extracted with EtOAc (3 × 45 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under

reduced pressure to provide **22** (0.450 g, 79%) as a colorless oil. The product was used without further purification. ¹H NMR (CDCl₃) δ 0.85–0.89 (t, *J* = 6 Hz, 2H, CH₃), 1.28 (brs, 6H, CH₂), 1.53–1.60 (m, 2H, CH₂), 2.54–2.59 (t, *J* = 8 Hz, 2H, CH₃), 4.06 (s, 2H, CH₂), 4.58 (s, 2H, CH₂), 7.0–7.30 (brm, 8H, Ar–H). ¹³C NMR (CDCl₃) δ 14.69, 23.20, 29.56, 32.03, 32.29, 36.19, 39.16, 63.72, 126.66, 127.37, 129.08, 129.17, 129.28, 131.48, 136.71, 138.52, 141.12, 143.42. IR (film) 3334 cm^{–1}.

2-(3-Methoxybenzyl)benzyl alcohol (23). Compound **23** was prepared from **18e** in a manner analogous to that of **22**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **23** (0.540 g, 75%) as a colorless oil. ¹H NMR (CDCl₃) δ 3.76 (s, 3H, OCH₃), 4.07 (s, 2H, Ar–CH₂–OH), 4.65 (s, 2H, Ar–CH₂–Ar), 6.7–6.76 (brm, 2H, Ar–H), 7.18–7.41 (brm, 6H, Ar–H). ¹³C NMR (CDCl₃) 39.06, 55.70, 63.79, 111.87, 115.21, 121.66, 127.44, 128.57, 128.96, 130.08, 131.15, 138.94, 139.41, 142.77, 159.88. IR (film) 3340 cm^{–1}.

2-[3-(*n*-Pentyloxy)benzyl]benzyl alcohol (24). Compound **24** was prepared from **18f** in a manner analogous to that of **22**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **24** (3.58 g, 100%) as a colorless oil. ¹H NMR (CDCl₃) δ 0.89–0.93 (t, *J* = 7 Hz, 3H, CH₃), 1.33–1.43 (m, 4H, CH₂), 1.56 (brs, 1H, OH), 1.70–1.76 (m, 2H, CH₂), 3.86–3.90 (t, *J* = 7 Hz, 2H, CH₂–O), 4.04 (s, 2H, Ar–CH₂–Ar), 4.64 (s, 2H, CH₂–OH), 6.68–6.71 (m, 2H, Ar–H), 6.74 (s, 1H, Ar–H), 7.14–7.28 (brm, 4H, Ar–H), 7.39–7.40 (m, 1H, Ar–H). ¹³C NMR (CDCl₃) δ 14.59, 23.05, 28.77, 29.55, 39.11, 63.81, 68.42, 112.46, 115.76, 121.43, 127.41, 128.55, 128.95, 130.02, 131.17, 139.14, 139.24, 142.68, 159.51.

4-*n*-Hexyl-2-(3-methoxybenzyl)benzyl alcohol (25). Compound **25** was prepared from **18h** in a manner analogous to that of **22**. The resulting oil was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **25** (2.21 g, 92%) as a colorless oil. ¹H NMR (CDCl₃) δ 0.85–0.89 (t, *J* = 6 Hz, 3H, CH₃), 1.26–1.29 (m, 6H, CH₂), 1.53–1.60 (m, 2H, CH₂), 2.54–2.59 (t, *J* = 8 Hz, 2H, CH₂–Ar), 3.76 (s, 3H, OCH₃), 4.03 (s, 2H, Ar–CH₂–Ar), 4.52 (s, 2H, CH₂–OH), 6.68–6.74 (m, 3H, Ar–H), 7.00–7.30 (brm, 4H, Ar–H). ¹³C NMR (CDCl₃) δ 14.62, 23.18, 29.54, 32.01, 32.28, 36.17, 39.16, 55.66, 63.75, 111.82, 115.10, 121.10, 127.41, 129.30, 130.02, 131.47, 136.70, 138.79, 143.03, 143.44. IR (film) 3365 cm^{–1}.

4-*n*-Hexyl-benzoylcyanide (26). Trimethylsilyl cyanide (0.62 mL, 4.67 mmol) was slowly added under N₂ to a well stirred solution of 4-*n*-hexylbenzoyl chloride (1.0 g, 4.45 mmol) in anhydrous CH₂Cl₂ (10 mL). Tin(IV) chloride (0.10 mL, 0.850 mmol) was added over 30 min to the solution at room temperature and the mixture was allowed to stir for 2.5 h, during which time the solution gradually turned from yellow to a dark brown. Ice-cold water (30 mL) was added, and the mixture was extracted with CH₂Cl₂ (3 × 30 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a brown oil. The oil was purified using medium pressure column chromatography (petroleum ether/acetone, 9.5:0.5) to provide **26** (0.820 g, 85%) as a pale-yellow oil. ¹H NMR (CDCl₃) δ 0.86–0.88 (t, *J* = 8 Hz, 3H, CH₃), 1.13 (s, 6H, CH₂), 1.60–1.65 (m, 2H, CH₂), 2.7–2.75 (t, *J* = 7.8 Hz, 2H, Ar–CH₂), 7.38–7.41 (d, *J* = 8 Hz, 2H, Ar–H), 8.04–8.07 (d, *J* = 8 Hz, 2H, Ar–H). ¹³C NMR (CDCl₃) δ 14.59, 23.08, 29.43, 31.37, 32.14, 36.92, 130.17, 131.25, 154.24. IR (film) 2221, 1687 cm^{–1}.

2-(4-Bromophenyl)-2-phenylacetonitrile (27). Bromine (0.82 g, 5.1 mmol) was slowly added over 1 h to 4-bromophenylacetonitrile (1.00 g, 5.10 mmol) at 110 °C (oil bath). The temperature was maintained between 105 and 110 °C for 30 min until the evolution of HBr had ceased. The solution was allowed to cool to room temperature, and a steady stream of nitrogen was passed over the solution (30 min). The resulting yellow oil was dissolved in anhydrous benzene (1.20 g, 15.0 mmol), and AlCl₃ (0.680 g, 5.10 mmol) was added. The solution was heated at reflux (3 h), cooled to room temperature, and poured onto ice (25 g). The solution was made acidic to pH 2 with 5% HCl and extracted with Et₂O (3 ×

35 mL). The organic extracts were combined, washed with water (50 mL), sat NaHCO₃ (50 mL), and brine (50 mL), dried (MgSO₄), and concentrated under reduced pressure to provide a pale-ellowsolid. The semisolid was recrystallized from absolute EtOH to provide **27** (0.650 g, 46%) as pale-yellow crystals; mp 80–82 °C. (lit⁴⁸ mp 79–81 °C). ¹H NMR (CDCl₃) δ 5.10 (s, 1H, CH), 7.21–7.53 (brm, 9H, Ar–H). IR (KBr) 2246 cm^{−1}.

(4-*n*-Hexylphenyl)(phenyl)methanone (28). AlCl₃ (2.36 g, 17.8 mmol) was added slowly at 0 °C to 4-*n*-hexylbenzoyl chloride (2.00 g, 8.90 mmol) in anhydrous benzene (50 mL). The suspension was warmed to room temperature and heated at reflux (2 h). The solution was then cooled to room temperature and poured onto ice (30.0 g). The suspension was made acidic with 5% HCl (≈ 50 mL) and extracted with EtOAc (3 × 45 mL). The organic extracts were combined, washed with sat NaHCO₃ (50 mL), water (50 mL) and brine (50 mL), dried (MgSO₄), and concentrated under reduced pressure to provide **28** (2.00 g, 87%) as a pale-yellow oil. The product was of sufficient purity to use in the next step. ¹H NMR (CDCl₃) δ 0.86–0.91 (t, *J* = 7 Hz, 2H, CH₃), 1.25 (s, 6H, CH₂), 1.62–1.67 (m, 2H, CH₂), 2.65–2.71 (t, *J* = 8 Hz, 2H, CH₂), 7.25–7.80 (brm, 9H, Ar–H). IR (film) 1662 cm^{−1}.

2-(4-*n*-Hexylphenyl)-2-hydroxy-2-phenylacetone (29). Trimethylsilyl cyanide (0.440 g, 4.51 mmol) was added to 4-*n*-hexylphenyl(phenyl)methanone (**28**, 1.00 g, 3.76 mmol) and zinc iodide (cat. amount) in CH₂Cl₂ (5 mL). The suspension was heated at reflux (2 h), cooled to room temperature, and concentrated under reduced pressure to provide a pale-yellow oil. The oil was dissolved in THF (5 mL), and 3 M HCl (3 mL) was added. The suspension was heated at reflux (1 h), cooled, and water (100 mL) was added. The mixture was extracted with EtOAc (3 × 20 mL), and the organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a pale-yellow oil that was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **29** (0.680 g, 62%) as a colorless oil. ¹H NMR (CDCl₃) δ 0.83–0.87 (t, *J* = 8 Hz, 2H, CH₃), 1.28 (s, 6H, CH₂), 1.53–1.58 (m, 2H, CH₂), 2.57–2.62 (t, *J* = 8 Hz, 2H, CH₂), 3.27 (brs, 1H, OH), 7.18–7.56 (brm, 9H, Ar–H). IR (film) 3403 cm^{−1}.

2-(4-*n*-Hexylphenyl)-2-phenylacetone (30). A NaBH₄ pellet (1.00 g, 26.4 mmol) was added to a well-stirred solution of 2-(4-*n*-hexylphenyl)-2-hydroxy-2-phenylacetone (**29**, 0.550 g, 1.88 mmol) in trifluoroacetic acid (15 mL). The viscous purple mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. Water (40 mL) was added, and the suspension was extracted with EtOAc (3 × 20 mL). The organic extracts were combined, dried (MgSO₄), and concentrated under reduced pressure to provide a pale-purple oil that was purified using medium pressure column chromatography (petroleum ether/acetone, 8:2) to provide **30** (0.350 g, 67%) as a colorless oil. ¹H NMR (CDCl₃) δ 0.85–0.89 (t, *J* = 8 Hz, 2H, CH₃), 1.28 (s, 6H, CH₂), 1.52–1.59 (m, 2H, CH₂), 2.55–2.60 (t, *J* = 7.8 Hz, 2H, CH₂), 5.20 (s, 1H, CH), 7.15–7.36 (brm, 9H, Ar–H). ¹³C NMR (CDCl₃) δ 14.64, 23.14, 29.51, 31.86, 32.24, 36.10, 42.85, 128.15, 128.28, 128.70, 129.74, 129.75. IR (film): 2246 cm^{−1}.

Molecular Modeling. Molecular modeling investigations were conducted using the SYBYL molecular modeling package (version 7.1, 2005, Tripos Associates, St. Louis, MO) on MIPS R14K- and R16K-based IRIX 6.5 Silicon Graphics Fuel and Tezro workstations. Molecular mechanics-based energy minimizations were performed using the Tripos Force Field with Gasteiger–Hückel charges, a distance-dependent dielectric constant $\epsilon = 4$, and a nonbonded interaction cutoff = 8 Å and were terminated at an energy gradient of 0.05 kcal/(mol·Å).

The primary sequences of the human dopamine D₃ (P35462), human muscarinic cholinergic M₁ (P11229), human vasopressin V_{1a} (P37288), human adrenergic β_2 (P07550), human δ -opioid (P41143), human 5-HT_{2A} (P28223), human dopamine D₂ (P14416), and bovine rhodopsin (P02699) receptors were retrieved from the ExPASy Proteomics Server (<http://www.expasy.org/>) at the Swiss Institute of Bioinformatics. An alignment profile consisting of the D₃, M₁, V_{1a}, β_2 , δ -opioid, and bovine rhodopsin receptors was

created that reproduced the alignment of Bissantz et al.⁷⁹ An unambiguous (i.e., highly conserved residues previously identified^{80,81} are aligned and there are no insertions or deletions in the helical regions) alignment of the 5-HT_{2A} sequence with the aforementioned profile was performed using the ClustalX⁸² program. Within ClustalX, the slow-accurate alignment algorithm was used, the BLOSUM matrix series⁸³ was employed, and the gap opening penalty was increased from 10.0 to 15.0 to help maintain the continuity of the transmembrane helical segments. As in Bissantz et al.,⁷⁹ the alignment was carried out in two separate steps: the first alignment included all residues from the *N*-terminus to the i3 loop and the second alignment included all residues from the i3 loop to the *C*-terminus. Manual adjustment of the ClustalX alignment was also required to properly align the disulfide-forming cysteine residues in the e2 loop. The D₂ sequence was subsequently aligned with that of 5-HT_{2A} to identify loci within the binding sites of the two receptors where cognate amino acids differ and to identify those that may be responsible for 5-HT_{2A}/D₂ selectivity. The resulting alignment is presented in Figure 3.

The alignment described above was used as the basis for subsequent homology modeling of the 5-HT_{2A} receptor. In light of the growing evidence^{35,79,84–91} that the binding of agonists versus antagonists may be more effectively modeled using at least two distinct static receptor models rather than a single static model, and our own observation that the agonist/antagonist properties of the 1-(2,5-dimethoxyphenyl)-2-aminopropane derivatives may be modulated by the nature of the substituent at the 4-position of the phenyl ring,¹⁵ separate agonist and antagonist 5-HT_{2A} models were generated. The automodel routine in the MODELER 8v1 software package^{92,93} was thus used to generate an initial population of 100 5-HT_{2A} receptor models. These models were constructed based on homology to bovine rhodopsin (chain A of PDB entry = 1U19), whose coordinates were downloaded from the RCSB Protein Data Bank (<http://www.rcsb.org>).

To maximize the variation in the side chain conformations of the MODELER-generated receptors, the residues falling within 12.0 Å of the retinal ligand in 1U19 were mutated to alanine. These residues are highlighted with a green background in Figure 3. This approach, which has been used to successfully model α_2 -adrenergic receptors,⁹⁴ allows MODELER to more fully explore side chain conformational space because the side chains may then be placed onto the backbone without the added constraints imposed by the existing rhodopsin sidechains. This also ameliorates the problem of retinal leaving behind a “ghost site” in the newly created 5-HT_{2A} receptors.⁹⁵

In addition to mutating the residues lining the 1U19 binding cavity to alanine, two other important aspects relating to the transfer of 3-D information from the 1U19 template to the 5-HT_{2A} models (particularly in the less well-conserved regions) were specifically addressed. First, instead of attempting to accurately model the i3 loop of 5-HT_{2A} (which is 40 residues longer than rhodopsin's), the backbone of the i3 loop of rhodopsin was transferred to the 5-HT_{2A} models and the residues therein mutated to glycine. These residues are highlighted with a purple background in Figure 3. This effectively created a tether that would keep the helices in place while having a minimal impact on the remaining portion of the receptor during minimizations and/or dynamics simulations. Pogozheva, Lomize, and Mosberg⁹⁶ have used a similar technique to build opioid receptors in which a contiguous primary amino acid sequence for the receptor was necessary. Second, because the *N*- and *C*-terminal domains of bovine rhodopsin and 5-HT_{2A} are very dissimilar in terms of both sequence homology and length, and because these domains are not believed to be important for the binding of small molecules,^{97,98} these features were not included in the 5-HT_{2A} models.

Each of the initial 100 5-HT_{2A} models thus generated was energy-minimized as described above with a maximum of 100000 iterations and with no constraints. The process of then selecting an agonist and an antagonist model from the receptor population was facilitated by the use of the automated docking program GOLD (version 3.0.1).^{99,100} A high-potency agonist (DOB, **2b**, *K*_i = 41 nM) and

an antagonist (ketanserin, $K_i = 0.4$ nM) were selected as reference ligands, and each was docked into all 100 receptors using the GOLD program. For DOB, separate docking runs were performed for each explicitly represented stereoisomer ((*R*)- and (*S*)- forms of **2b** = 2 isomers) because each isomer shows low nanomolar binding affinity at the 5-HT_{2A} receptor. Standard default settings were used (no speed-up), early termination was disabled, and 10 genetic algorithm (GA) runs were performed for each ligand. The ChemScore¹⁰¹ fitness function was used, and the binding site was defined to include all residues within a 15.0 Å radius of the D155^{3,32} C γ carbon atom. A docking constraint was also enforced that biased the docking results toward solutions in which the ligand was hydrogen bonded to the conserved D155^{3,32} side chain. When these initial docking runs were complete, the lists of ChemScores for each isomer were tabulated (each reference ligand isomer was docked into each of the 100 MODELER-generated receptors) and sorted best to worst (highest to lowest for ChemScore in GOLD). The top-scoring complexes for each reference ligand are summarized in Supporting Information Table 4.

The top-scoring receptor–ligand complexes for each of the reference compounds were then inspected visually to ensure that the receptor formed a chemically intuitive complex with the ligand and that the receptor–ligand complex could account for the observed point mutation data. High-scoring complexes that did not meet this requirement were discarded. Ligand–receptor complexes were discarded for a variety of reasons, including: (1) the docked solution for DOB did not accept a hydrogen bond from the receptor at either the 2- or 5-position (rationale: methoxy groups are necessary for high affinity of the smaller 4-substituted phenylethylamines [$K_i = 1770$ nM, **3b**; $K_i = 41$ nM, **2b**]), (2) the docked solution for DOB did not interact with F340 (rationale: DOB most likely binds in the receptor site in the same manner as does DOI (Supporting Information Figure 2), which loses all affinity for the F340A mutant (Table 2)), (3) the docked solution for ketanserin could not explain the effects of mutagenesis at F340, Y370, and/or W76 (Table 3), and (4) the e2 loop of the receptor was incorrectly modeled (rationale: MODELER occasionally placed the e2 loop segment that joins the top of TM4 to the disulfide bond farther down in the receptor site than the segment joining the disulfide bond to the top of TM5—the reverse of what is seen in the bovine rhodopsin crystal structure). A complete listing of the 12 top-scoring receptor–reference ligand complexes and comments on their binding modes is presented in Supporting Information Table 4.

The ChemScores for the 100 top complexes covered a wide range (*R*(–)-DOB, 1.41–33.52; *S*(+)-DOB, 3.06–30.71; ketanserin, –31.84–35.21), a result of the receptor population containing members that exhibited both very high and very low degrees of complementarity to the docked ligands. The top-scoring receptors for a given ligand tended to have similar high scores (Supporting Information Table 4), but the corresponding binding modes of the docked ligands were very different. It was thus necessary to use additional information from receptor mutagenesis and ligand SAR to eliminate from consideration those that were not consistent with this data and to select the most appropriate receptor models (vide supra). Of course, reconciliation of relevant experimentally derived data with molecular models is a necessary part of any modeling study. Seven of the top 12 receptor models are common to both *R*(–)-DOB and *S*(+)-DOB. Interestingly, five of the top 12 receptor models for ketanserin are also found in the top receptor lists of either *R*(–)-DOB or *S*(+)-DOB. It should also be noted that for a given receptor–ligand model, the set of docked solutions from the 10 GA runs tended to be qualitatively similar, differing only slightly in the ligands' relative position and orientation within the binding site. For each of the reference ligands, then, the final receptor model chosen was the highest scoring chemically intuitive complex. For DOB, the same receptor model was coincidentally chosen for each of the two stereoisomers. In this selected agonist model, the DOB isomers docked in a similar fashion (Supporting Information Figure 2).

The agonist and antagonist 5-HT_{2A} models were subsequently analyzed using PROCHECK¹⁰² and the ProTable facility within

SYBYL to assess the geometric integrity of various structural elements (bond lengths, torsion angles, etc.) within each receptor. Unusual and unfavorable geometries were interactively corrected as necessary. There were two such regions in both the agonist and antagonist receptors. The first involved the region of TM7 proximal to position 7.43, where the retinal chromophore is covalently bound in rhodopsin. Backbone geometries in this region were visibly nonoptimal (kinked), so the residues in the region V364^{7,37} to A374^{7,47} were assigned ideal α helix coordinates using SYBYL 7.1. A second visibly distorted region at location L236^{5,40} to V241^{5,45} was refined in a similar way. The modified receptors were then energy-minimized as described for the initial 5-HT_{2A} receptors prior to docking. The final models are depicted together with the A chain of rhodopsin (1U19) in Supporting Information Figure 1.

Ligand molecules were sketched manually using SYBYL 7.1 (Tripos, Inc., St. Louis, MO) and assigned three-dimensional coordinates using the CONCORD (v.6.1.0) facility within SYBYL. Because the synthesized and tested compounds are racemic mixtures in most if not all cases, *R/S* isomers were explicitly represented for each ligand where necessary. GOLD was used to dock the ligands into the agonist and antagonist 5-HT_{2A} models in an automated fashion under the same conditions as described above for the receptor selection phase. Ligand preference for a particular receptor was determined by the difference in the ChemScore fitness function values for the agonist and antagonist receptor solutions (Supporting Information Table 2). However, there was one exception: AMDA (**1a**), which was predicted to have a slight preference for the agonist receptor, was associated with the antagonist model on the strength of the F340^{6,52}L mutation data, as described earlier. Final docked ligand–receptor complexes were energy-minimized as described above for the initial 5-HT_{2A} models. The minimized complexes were further subjected to a short molecular dynamics simulation (Tripos Force Field, Gasteiger–Hückel charges, distance-dependent dielectric = 4.0, fixed aggregate = all residues >8.0 Å from the GOLD-docked solution, 100 ps simulation time, 300 K) to provide further evidence of the veracity of the docked solutions.

Affinity Determinations. Binding assays and data analysis were performed as previously described using [³H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-HT_{2A} receptor (GF-62 cells).¹⁰³ The F339L and F340L mutants were prepared and assayed as previously described.¹⁰⁴

Acknowledgment. This work was supported by United States Public Health Service grant MH57969 (R.B.W.), R01MH61887, U19MH082441 (B.L.R.), and the NIMH Psychoactive Drug Screening Program (B.L.R.).

Supporting Information Available: Receptor–ligand interatomic distances; GOLD-ChemScore fitness function values; elemental microanalysis; initial docking results for DOB and ketanserin, rhodopsin template and 5-HT_{2A} receptor model backbone traces; docked solutions for DOB and DOI: agonist receptor model; docked solutions for the four isomers of **1c**: antagonist receptor model; docked solutions for *S*-**1c** and *R*-**2c**: antagonist receptor model. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- (1) Roth, B. L. Multiple Serotonin Receptors: Clinical and Experimental Aspects. *Ann. Clin. Psych.* **1994**, *6*, 67–78.
- (2) Kroeze, W. K.; Kristiansen, K.; Roth, B. L. Molecular Biology of Serotonin Receptors—Structure and Function at the Molecular Level. *Curr. Top. Med. Chem.* **2002**, *2*, 507–528.
- (3) Glennon, R. A.; Dukat, M.; Westkaemper, R. B. Serotonin Receptors and Ligands. In *Psychopharmacology: The Fourth Generation of Progress*; Bloom, F. E.; Kupfer, D. J., Eds.; Raven Press: New York, 1999.
- (4) Glennon, R. A.; Dukat, M. Novel Serotonergic Agents: 5-HT₂ Update 1997. *Serotonin ID Res. Alert* **1997**, *2*, 107–113.
- (5) Runyon, S. P.; Peddi, S.; Savage, J. E.; Roth, B. L.; Glennon, R. A.; Westkaemper, R. B. Geometry–Affinity Relationships of the Selective Serotonin Receptor Ligand 9-(Aminomethyl)-9,10-dihydroanthracene. *J. Med. Chem.* **2002**, *45*, 1656–1664.

- (6) Runyon, S. P.; Savage, J. E.; Taroua, M.; Roth, B. L.; Glennon, R. A.; Westkaemper, R. B. Influence of Chain Length and *N*-Alkylation on the Selective Serotonin Receptor Ligand 9-(Aminomethyl)-9,10-dihydroanthracene. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 655–658.
- (7) Westkaemper, R. B.; Glennon, R. A. Application of Ligand SAR, Receptor Modeling and Receptor Mutagenesis to the Discovery and Development of a New Class of 5-HT_{2A} Ligands. *Curr. Top. Med. Chem.* **2002**, *2*, 575–598.
- (8) Westkaemper, R. B.; Runyon, S. P.; Bondarev, M. L.; Savage, J. E.; Roth, B. L.; Glennon, R. A. 9-(Aminomethyl)-9,10-dihydroanthracene is a Novel and Unlikely 5-HT_{2A} Receptor Antagonist. *Eur. J. Pharmacol.* **1999**, *380*, R5–R7.
- (9) Westkaemper, R. B.; Runyon, S. P.; Savage, J. E.; Roth, B. L.; Glennon, R. A. Exploring the Relationship Between Binding Modes of 9-(Aminomethyl)-9,10-dihydroanthracene and Cyproheptadine Analogues at the 5-HT_{2A} Serotonin Receptor. *Bioorg. Med. Chem. Lett.* **2001**, *11*, 563–566.
- (10) Rabideau, P. The Conformational Analysis of 1,4-cyclohexadienes: 1,4-dihydrobenzenes, 1,4-dihydronaphthalenes and 9,10-dihydroanthracenes. *Acc. Chem. Res.* **1978**, *11*, 141–147.
- (11) Glennon, R. A.; Liebowitz, S. M.; Anderson, G. M. I. Serotonin Receptor Affinities of Psychoactive Phenylalkylamine Derivatives. *J. Med. Chem.* **1980**, *23*, 294–299.
- (12) Glennon, R. A.; Young, R.; Benington, F.; Morin, R. D. Behavioral and Serotonin Receptor Properties of 4-Substituted Derivatives of the Hallucinogen 1-(2,5-Dimethoxy)-2-aminopropane. *J. Med. Chem.* **1982**, *25*, 1163–1168.
- (13) Seggel, M. R.; Yousif, M. Y.; Lyon, R. A.; Titeler, M.; Roth, B. L.; Suba, E. A.; Glennon, R. A. A Structure-Affinity Study of the Binding of 4-Substituted Analogues of 1-(2,5-Dimethoxyphenyl)-2-aminopropane at 5-HT₂ Serotonin Receptors. *J. Med. Chem.* **1990**, *33*, 1032–1036.
- (14) Kornfeld, E. C. Raney Nickel Hydrogenolysis of Thioamides: A New Amine Synthesis. *J. Org. Chem.* **1951**, *16*, 131–138.
- (15) Dowd, C. S.; Herrick-Davis, K.; Egan, C.; DuPre, A.; Smith, C.; Teitler, M.; Glennon, R. A. 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT_{2A} Partial Agonists. *J. Med. Chem.* **2000**, *43*, 3074–3084.
- (16) Pine, S. H.; Shen, G. S.; Hoang, H. Ketone Methylenation Using the Tebbe and Wittig Reagents—A Comparison. *Synthesis* **1991**, *1991*, 165–166.
- (17) Snyder, S. E.; Avilez-Garay, F. A.; Chakraborti, R.; Nichols, D. E.; Watts, V. J.; Mailman, R. B. Synthesis and Evaluation of 6,7-Dihydroxy-2,3,4,8,9,13b-hexahydro-1H-benzo[6,7]cyclohepta[1,2,3-*ef*][3]benzazepine, 6,7-Dihydroxy-1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-Aminomethyl-9,10-dihydro-1,2-dihydroxyanthracene as Conformationally Restricted Analogs of β -Phenyldopamine. *J. Med. Chem.* **1995**, *38*, 2395–2409.
- (18) Ashwood, M. S.; Bell, L. A.; Houghton, P. G.; Wright, S. H. B. Synthesis of 1,1-Diaryl-2,2-dimethoxyethanes. *Synthesis* **1988**, *1988*, 379–381.
- (19) Bellamy, F. D.; Ou, K. Selective Reduction of Aromatic Nitro Compounds with Stannous Chloride in Nonacidic and Nonaqueous Medium. *Tetrahedron Lett.* **1984**, *25*, 839–842.
- (20) Meek, J. S.; Dann, J. R.; Poon, B. T. Diels-Alder Reactions of 9-Substituted Anthracenes. II. 9-Cyanoanthracene. *J. Am. Chem. Soc.* **1956**, *78*, 5413–5416.
- (21) Miyaura, N.; Ishiyama, T.; Sasaki, H.; Ishikawa, M.; Sato, M.; Suzuki, A. Palladium-Catalyzed Inter- and Intramolecular Cross-Coupling Reactions of B-Alkyl-9-borabicyclo[3.3.1]nonane Derivatives with 1-Halo-1-alkenes or Haloarenes. *J. Am. Chem. Soc.* **1989**, *111*, 314–321.
- (22) Olah, G. A.; Arvanaghi, M.; Surya Prakash, G. K. Tin(IV) Chloride-Catalyzed Preparation of Aroyl Cyanides from Aroyl Chlorides and Cyanotrimethylsilane. *Synthesis* **1983**, *1983*, 636–637.
- (23) Kandler, K.; Hedemann, B.; Schärfe, E. Studien über den Mechanismus Chemischer Reaktionen. X. Phenyl- und Cyclohexyl-alkylamine durch Hydrierung. *Justus Liebigs Ann. Chem.* **1948**, *560*, 215–222.
- (24) Robb, C. M.; Schultz, E. M. Diphenylacetonitrile. *Org. Synth. Coll.* **1955**, *3*, 347–349.
- (25) Gribble, G. W.; Leese, R. M.; Evans, B. E. Reactions of Sodium Borohydride in Acidic Media: IV. Reduction of Diarylmethanols and Triarylmethanols in Trifluoroacetic Acid. *Synthesis* **1977**, *1977*, 172–176.
- (26) Jacoby, E.; Fauchère, J.-L.; Raimbaud, E.; Ollivier, S.; Michel, A.; Spedding, M. A Three Binding Site Hypothesis for the Interaction of Ligands with Monoamine G Protein-coupled Receptors: Implications for Combinatorial Ligand Design. *Quantum Struct.—Act. Relat.* **1999**, *18*, 561–572.
- (27) Surgand, J.-S.; Rodrigo, J.; Kellenberger, E.; Rognan, D. A Chemogenomic Analysis of the Transmembrane Binding Cavity of Human G-Protein-Coupled Receptors. *Proteins* **2006**, *62*, 509–538.
- (28) Glennon, R. A.; Westkaemper, R. B. Serotonin Receptors, 5-HT Ligands and Receptor Modeling. In *Trends in Receptor Research*; Angeli, P.; Gulini, U.; Quaglia, W., Eds.; Elsevier: Amsterdam, 1992; pp 185–207.
- (29) Westkaemper, R. B.; Glennon, R. A. Molecular Graphics Models of the 5-HT₂ Subfamily: 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C} Receptors. *Med. Chem. Res.* **1993**, *3*, 317–334.
- (30) Westkaemper, R. B.; Hyde, E. G.; Choudhary, M. S.; Khan, N.; Gelbar, E. I.; Glennon, R. A.; Roth, B. L. Engineering a Region of Bulk Tolerance in the 5-HT_{2A} Receptor. *Eur. J. Med. Chem.* **1999**, *34*, 441–447.
- (31) Kuipers, W.; van Wijngaarden, I.; Ijzerman, A. P. A Model of the Serotonin 5-HT_{1A} Receptor: Agonist and Antagonist Binding Sites. *Drug Des. Discovery* **1994**, *11*, 231–249.
- (32) Teodoro, M. L.; Kavraki, L. E. Conformational Flexibility Models for the Receptor in Structure Based Drug Design. *Curr. Pharm. Des.* **2003**, *9*, 1635–1648.
- (33) Unless specified otherwise, the receptor sequence number for a particular amino acid residue is listed first, followed by its Ballesteros–Weinstein¹¹⁰ residue identifier as a superscript. Following the convention of Xhaard et al.,⁹⁴ the positions of the residues in the e2 (x12) loop are given relative to the cysteine residue that forms the disulfide bond with position 3.25 of TM3 and is assigned the identifier x12.50. Thus, this reference residue is referred to as C227^{x12.50} in the 5-HT_{2A} receptor.
- (34) Salom, D.; Lodowsky, D. T.; Stenkamp, R. E.; Le Trong, I.; Golczak, M.; Jastrzebska, B.; Harris, T.; Ballesteros, J. A.; Palczewski, K. Crystal Structure of a Photoactivated Deprotonated Intermediate of Rhodopsin. *Proc. Nat. Acad. Sci. U.S.A.* **2006**, *103*, 16123–16128.
- (35) Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J. A.; Javitch, J. A. β_2 Adrenergic Receptor Activation: Modulation of the Proline Kink in Transmembrane 6 by a Rotamer Toggle Switch. *J. Biol. Chem.* **2002**, *277*, 40989–40996.
- (36) Ariens, E. J. A General Introduction. In *Drug Design*; Ariens, E. J., Ed.; Academic Press: New York, 1971; pp 173–192.
- (37) Glennon, R. A.; Westkaemper, R. B.; Bartyzel, P. Medicinal Chemistry of Serotonergic Agents. In *Serotonin Receptor Subtypes*; Peroutka, S. J., Ed.; Wiley-Liss: New York, 1991; pp 19–64.
- (38) Stevenson, G. I.; Smith, A. L.; Lewis, S.; Michie, S. G.; Neduvellil, J. G.; Patel, S.; Marwood, R.; Patel, S.; Castro, J. L. 2-Aryl Tryptamines: Selective High-Affinity Antagonists for the h5-HT_{2A} Receptor. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2697–2699.
- (39) Bennett, J. P.; Snyder, S. H. Stereospecific Binding of D-Lysergic Acid Diethylamide (LSD) to Brain Membranes: Relationship to Serotonin Receptors. *Brain Res.* **1975**, *94*, 523–544.
- (40) Glennon, R. A.; Dukat, M.; el-Burmawy, M.; Law, H.; de los Angeles, J.; Teitler, M.; King, A.; Herrick-Davis, K. Influence of Amine Substituents on 5-HT_{2A} Versus 5-HT_{2C} Binding of Phenylalkyl- and Indolylalkylamines. *J. Med. Chem.* **1994**, *37*, 1929–1935.
- (41) Roth, B. L.; Berry, S. A.; Kroeze, W. K.; Willins, D. L.; Kristiansen, K. Serotonin 5-HT_{2A} Receptors: Molecular Biology and Mechanisms of Regulation. *Crit. Rev. Neurobiol.* **1998**, *12*, 319–338.
- (42) Parrish, J. C.; Braden, M. R.; Gundy, E.; Nichols, D. E. Differential Phospholipase C Activation by Phenylalkylamine Serotonin 5-HT_{2A} Receptor Agonists. *J. Neurochem.* **2005**, *95*, 1575–1584.
- (43) Süel, G.; Lockless, S. W.; Wall, M. A.; Ranganathan, R. Evolutionarily Conserved Networks of Residues Mediate Allosteric Communication in Proteins. *Nat. Struct. Biol.* **2003**, *10*, 59–69.
- (44) Roth, B. L.; Shoham, M.; Choudhary, M. S.; Khan, N. Identification of Conserved Aromatic Residues Essential for Agonist Binding and Second Messenger Production at 5-Hydroxytryptamine_{2A} Receptors. *Mol. Pharmacol.* **1997**, *52*, 259–266.
- (45) Almaula, N.; Ebersole, B. J.; Zhang, D.; Weinstein, H.; Sealfon, S. C. Mapping the Binding Site Pocket of the Serotonin 5-Hydroxytryptamine_{2A} Receptor. Ser3.36(159) Provides a Second Interaction Site for the Protonated Amine of Serotonin but not of Lysergic Acid Diethylamide or Bufotenin. *J. Biol. Chem.* **1996**, *271*, 14672–14675.
- (46) Johnson, M. P.; Wainscott, D. B.; Lucaites, V. L.; Baez, M.; Nelson, D. L. Mutations of Transmembrane IV and V Serines Indicate that All Tryptamines Do Not Bind to the Rat 5-HT_{2A} Receptor in the Same Manner. *Mol. Brain Res.* **1997**, *49*, 1–6.
- (47) Shapiro, D. A.; Kristiansen, K.; Kroeze, W. K.; Roth, B. L. Differential Modes of Agonist Binding to 5-Hydroxytryptamine_{2A} Serotonin Receptors Revealed by Mutation and Molecular Modeling of Conserved Residues in Transmembrane Region 5. *Mol. Pharmacol.* **2000**, *58*, 877–886.
- (48) Grånäs, C.; Nordvall, G.; Larhammar, D. Site-directed Mutagenesis of the Human 5-HT_{1B} Receptor. *Eur. J. Med. Chem.* **1998**, *349*, 367–375.
- (49) Hwa, J.; Graham, R. M.; Perez, D. M. Chimeras of α_1 -Adrenergic Receptor Subtypes Identify Critical Residues that Modulate Active State Isomerization. *J. Biol. Chem.* **1996**, *271*, 7956–7964.

- (50) Lundstrom, K.; Turpin, M. P.; Large, C.; Robertson, G.; Thomas, P.; Lewell, X. -Q. Mapping of Dopamine D₃ Receptor Binding Site by Pharmacological Characterization of Mutants Expressed in CHO Cells with the Semliki Forest Virus System. *J. Recept. Signal Transduction Res.* **1998**, *18*, 133–150.
- (51) Weiland, K.; ter Laak, A. M.; Smit, M. J.; Kühne, R.; Timmerman, H.; Leurs, R. Mutational Analysis of the Antagonist-Binding Site of the Histamine H₁ Receptor. *J. Biol. Chem.* **1999**, *274*, 29994–30000.
- (52) Weiland, K.; Zuurmond, H. M.; Krasel, C.; Ijzerman, A. P.; Lohse, M. J. Involvement of Asn-293 in Stereospecific Agonist Recognition and in Activation of the β_2 -Adrenergic Receptor. *Proc. Nat. Acad. Sci. U.S.A.* **1996**, *93*, 9276–9281.
- (53) Zuurmond, H. M.; Hessling, J.; Blüml, K.; Lohse, M. J.; Ijzerman, A. P. Study of Interaction between Agonists and Asn293 in Helix VI of Human β_2 -Adrenergic Receptor. *Mol. Pharmacol.* **1999**, *56*, 909–916.
- (54) Javitch, J. A.; Ballesteros, J. A.; Weinstein, H.; Chen, J. A Cluster of Aromatic Residues in the Sixth Membrane-Spanning Segment of the Dopamine D₂ Receptor is Accessible in the Binding-Site Crevise. *Biochemistry* **1998**, *37*, 998–1006.
- (55) Yao, X.; Parnot, C.; Deupi, X.; Ratnala, V. R. P.; Swaminath, G.; Farrens, D.; Kobilka, B. Coupling Ligand Structure to Specific Conformational Switches in the β_2 -Adrenoceptor. *Nat. Chem. Biol.* **2006**, *2*, 417–422.
- (56) Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G. F.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the β_2 -Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6. *J. Biol. Chem.* **2001**, *276*, 29171–29177.
- (57) Perola, E.; Charifson, P. S. Conformational Analysis of Druglike Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding. *J. Med. Chem.* **2004**, *47*, 2499–2510.
- (58) Stockwell, G. R.; Thornton, J. M. Conformational Diversity of Ligands Bound to Proteins. *J. Mol. Biol.* **2006**, *356*, 928–944.
- (59) Glennon, R. A.; Metwally, K.; Dukat, M.; Ismael, A. M.; De Los Angeles, J.; Herndon, J.; Teitler, M.; Khorana, N. Ketanserin and Spiperone as Templates for Novel Serotonin 5-HT_{2A} Antagonists. *Curr. Top. Med. Chem.* **2002**, *2*, 539–558.
- (60) Squillacote, M.; S., S. R.; Chapman, O. L.; Anet, F. A. L. Spectroscopic Detection of the Twist-Boat Conformation of Cyclohexane. A Direct Measurement of the Free Energy Difference between the Chair and the Twist-Boat. *J. Am. Chem. Soc.* **1975**, *97*, 3244–3246.
- (61) Bostrom, J.; Norrby, P. O.; Liljefors, T. Conformational Energy Penalties of Protein-Bound Ligands. *J. Comput.-Aided Mol. Des.* **1998**, *12*, 383–396.
- (62) Nicklaus, M. C.; Wang, S.; Driscoll, J. S.; Milne, G. W. Conformational Changes of Small Molecules Binding to Proteins. *Bioorg. Med. Chem.* **1995**, *3*, 411–428.
- (63) Dezi, C.; Brea, J.; Alvarado, M.; Raviña, E.; Masaguer, C. F.; Loza, M. I.; Sanz, F.; Pastor, M. Multistructure 3D-QSAR Studies on a Series of Conformationally Constrained Butyrophenones Docked into a New Homology Model of the 5-HT_{2A} Receptor. *J. Med. Chem.* **2007**, *50*, 3242–3255.
- (64) Schetz, J. A.; Benjamin, P. S.; Sibley, D. R. Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D₄ Dopamine Receptor Are Molecular Determinants of D₄-Selective Pharmacology. *Mol. Pharmacol.* **2000**, *57*, 144–152.
- (65) Simpson, M. M.; Ballesteros, J. A.; Chiappa, V.; Chen, J.; Suehiro, M.; Hartman, D. S.; Godel, T.; Snyder, L. A.; Sakmar, T. P.; Javitch, J. A. Dopamine D₄/D₂ Receptor Selectivity is Determined by a Divergent Aromatic Microdomain Contained Within the Second, Third, and Seventh Membrane-Spanning Segments. *Mol. Pharmacol.* **1999**, *56*, 1116–1126.
- (66) Boess, F. G.; Monsma, F. J. J.; Sleight, A. J. Identification of Residues in Transmembrane Regions III and VI that Contribute to the Ligand Binding Site of the Serotonin 5-HT₆ Receptor. *J. Neurochem.* **1998**, *71*, 2169–2177.
- (67) Lu, Z.-L.; Hulme, E. C. The Functional Topography of Transmembrane Domain 3 of the M₁ Muscarinic Acetylcholine Receptor, Revealed by Scanning Mutagenesis. *J. Biol. Chem.* **1999**, *274*, 7309–7315.
- (68) Matsui, H.; Lazareno, S.; Birdsall, N. J. M. Probing the Location of the Allosteric Site on M₁ Muscarinic Receptors by Site-Directed Mutagenesis. *Mol. Pharmacol.* **1995**, *47*, 88–98.
- (69) Daniell, S. J.; Strange, P. G.; Naylor, L. H. Site-directed Mutagenesis of Tyr417 in the Rat D₂ Dopamine Receptor. *Biochem. Soc. Trans.* **1994**, *22*, 144S.
- (70) Fu, D.; Ballesteros, J. A.; Weinstein, H.; Chen, J.; Javitch, J. A. Residues in the Seventh Membrane-Spanning Segment of the Dopamine D₂ Receptor Accessible in the Binding-Site Crevise. *Biochemistry* **1996**, *35*, 11278–11285.
- (71) Rezmann-Vitti, L. A.; Nero, T. L.; Jackman, G. P.; Machida, C. A.; Duke, B. J.; Louis, W. J.; Louis, S. N. S. Role of Tyr^{356(7.43)} and Ser^{190(4.57)} in Antagonist Binding in the Rat β_1 -Adrenergic Receptor. *J. Med. Chem.* **2006**, *49*, 3467–3577.
- (72) Adham, N.; Tamm, J. A.; Salton, J. A.; Vaysse, P. J.-J.; Weinschank, R. L.; Branchek, T. A. A Single Point Mutation Increases the Affinity of Serotonin 5-HT_{1D α} , 5-HT_{1D β} , 5-HT_{1E}, and 5-HT_{1F} Receptors for β -adrenergic Antagonists. *Neuropharmacology* **1994**, *33*, 387–391.
- (73) Glennon, R. A.; Dukat, M.; Westkaemper, R. B.; Ismael, A. M.; Izzarelli, D. G.; Parker, E. M. The Binding of Propranolol at 5-Hydroxytryptamine_{1D β} T355N Mutant Receptors May Involve Formation of Two Hydrogen Bonds to Asparagine. *Mol. Pharmacol.* **1996**, *49*, 198–206.
- (74) Guan, X.-M.; Peroutka, S. J.; Kobilka, B. K. Identification of a Single Amino Acid Residue Responsible for the Binding of a Class of β -Adrenergic Receptor Antagonists to 5-Hydroxytryptamine_{1A} Receptors. *Mol. Pharmacol.* **1992**, *41*, 695–698.
- (75) Kuipers, W.; Link, R.; Standaar, P. J.; Stoit, A. R.; van Wijngaarden, I.; Leurs, R.; Ijzerman, A. P. Study of the Interaction between Aryloxypropanolamines and Asn386 in Helix VII of the Human 5-Hydroxytryptamine_{1A} Receptor. *Mol. Pharmacol.* **1997**, *51*, 889–896.
- (76) Oksenberg, D.; Marsters, S. A.; O'Dowd, B. F.; Jin, H.; Havlik, S.; Peroutka, S. J.; Ashkenazi, A. A Single Amino Acid Difference Confers Major Pharmacological Variation between Human and Rodent 5-HT_{1B} Receptors. *Nature* **1992**, *360*, 161–163.
- (77) Suryanarayana, S.; Daunt, D. A.; von Zastrow, M.; Kobilka, B. K. A Point Mutation in the Seventh Hydrophobic Domain of the α_2 Adrenergic Receptor Increases Its Affinity for a Family of β Receptor Antagonists. *J. Biol. Chem.* **1991**, *266*, 15488–15492.
- (78) Suryanarayana, S.; Kobilka, B. K. Amino Acid Substitutions at Position 312 in the Seventh Hydrophobic Segment of the β_2 -Adrenergic Receptor Modify Ligand-Binding Specificity. *Mol. Pharmacol.* **1993**, *44*, 111–114.
- (79) Bissantz, C.; Bernard, P.; Hilbert, M.; Rognan, D. Protein-Based Virtual Screening of Chemical Databases. II. Are Homology Models of G-Protein Coupled Receptors Suitable Targets? *Proteins* **2003**, *50*, 5–25.
- (80) Baldwin, J. M. The Probable Arrangement of the Helices in G Protein-Coupled Receptors. *EMBO J.* **1993**, *12*, 1693–1703.
- (81) Baldwin, J. M.; Schertler, G. F. X.; Unger, V. M. An Alpha-Carbon Template for the Transmembrane Helices in the Rhodopsin Family of G-Protein-Coupled Receptors. *J. Mol. Biol.* **1997**, *272*, 144–164.
- (82) Chenna, R.; Sugawara, H.; Koike, T.; Lopez, R.; Gibson, T. J.; Higgins, D. G.; Thompson, J. D. Multiple Sequence Alignment with the Clustal Series of Programs. *Nucleic Acids Res.* **2003**, *31*, 3497–3500.
- (83) Henikoff, S.; Henikoff, J. G. Amino Acid Substitution Matrices from Protein Blocks. *Proc. Nat. Acad. Sci. U.S.A.* **1992**, *89*, 10915–10919.
- (84) Bissantz, C. Conformational Changes of G Protein-Coupled Receptors During their Activation by Agonist Binding. *J. Recept. Signal Transduct.* **2003**, *23*, 123–152.
- (85) Crocker, E.; Eilers, M.; Ahuja, S.; Hornak, V.; Hirshfeld, A.; Sheves, M.; Smith, S. O. Location of Trp265 in Metarhodopsin II: Implications for the Activation Mechanism of the Visual Receptor Rhodopsin. *J. Mol. Biol.* **2006**, *357*, 163–172.
- (86) Hallmen, C.; Wiese, M. Molecular Dynamics Simulation of the Human Adenosine A₃ Receptor: Agonist Induced Conformational Changes of Trp243. *J. Comput.-Aided Mol. Des.* **2006**, *20*, 673–684.
- (87) Niv, M. Y.; Skrabanek, L.; Filizola, M.; Weinstein, H. Modeling Activated States of GPCRs: The Rhodopsin Template. *J. Comput.-Aided Mol. Des.* **2006**, *20*, 437–448.
- (88) Patel, A. B.; Crocker, E.; Eilers, M.; Hirshfeld, A.; Sheves, M.; Smith, S. O. Coupling of Retinal Isomerization to the Activation of Rhodopsin. *Proc. Nat. Acad. Sci. U.S.A.* **2004**, *101*, 10048–10053.
- (89) Singh, R.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Guarnieri, F. Activation of the Cannabinoid CB₁ Receptor may Involve a W648/F336 Rotamer Toggle Switch. *J. Pept. Res.* **2002**, *60*, 357–370.
- (90) Spooner, P. J. R.; Sharples, J. M.; Goodall, S. C.; Bovee-Geurts, P. H. M.; Verhoeven, M. A.; Lugtenburg, J.; Pistorius, A. M. A.; DeGrip, W. J.; Watts, A. The Ring of the Rhodopsin Chromophore in a Hydrophobic Activation Switch Within the Binding Pocket. *J. Mol. Biol.* **2004**, *343*, 719–730.
- (91) Swaminath, G.; Deupi, X.; Lee, T. W.; Zhu, W.; Thain, F. S.; Kobilka, T. S.; Kobilka, B. K. Probing the β_2 Adrenoceptor Binding Site with Catechol Reveals Differences in Binding and Activation by Agonists and Partial Agonists. *J. Biol. Chem.* **2005**, *280*, 22165–22171.
- (92) Fiser, A.; Šali, A. MODELLER: Generation and Refinement of Homology-based Protein Structure Models. In *Methods in Enzymology: Macromolecular Crystallography: Part D*, Carter, C. W. J.; Sweet, R. M., Eds.; Academic Press: New York, 2003; Vol. 374, pp 461–491.

- (93) Sali, A.; Blundell, T. L. Comparative Protein Modelling by Satisfaction of Spatial Restraints. *J. Mol. Biol.* **1993**, *234*, 779–815.
- (94) Xhaard, H.; Nyrönen, T.; Rantanen, V.-V.; Ruuskanen, J. O.; Laurila, J.; Salminen, T.; Scheinin, M.; Johnson, M. S. Model Structures of α -2 Adrenoreceptors in Complex with Automatically Docked Antagonist Ligands Raise the Possibility of Interactions Dissimilar from Agonist Ligands. *J. Struct. Biol.* **2005**, *150*, 126–143.
- (95) Westkaemper, R. B.; Roth, B. L. Structure and Function Reveals Insights in the Pharmacology of 5-HT Receptor Subtypes. In *The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics*, Roth, B. L., Ed.; Humana Press: Totowa, NJ, 2006.
- (96) Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Opioid Receptor Three-Dimensional Structures from Distance Geometry Calculations with Hydrogen Bonding Constraints. *Biophys. J.* **1998**, *75*, 612–634.
- (97) Meng, F.; Hoversten, M. T.; Thompson, R. C.; Taylor, L.; Watson, S. J.; Akil, H. A Chimeric Study of the Molecular Basis of Affinity and Selectivity of the κ and δ Opioid Receptors. Potential Role of Extracellular Domains. *J. Biol. Chem.* **1995**, *270*, 12730–12736.
- (98) Watson, B.; Meng, F.; Akil, H. A Chimeric Analysis of the Opioid Receptor Domains Critical for the Binding Selectivity of μ Opioid Receptors. *Neurobiol. Dis.* **1996**, *3*, 87–96.
- (99) Jones, G.; Willett, P.; Glen, R. C. Molecular Recognition of Receptor Sites using a Genetic Algorithm with a Description of Desolvation. *J. Mol. Biol.* **1995**, *245*, 43–53.
- (100) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. *J. Mol. Biol.* **1997**, *267*, 727–748.
- (101) Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical Scoring Functions: I. The Development of a Fast Empirical Scoring Function to Estimate the Binding Affinity of Ligands in Receptor Complexes. *J. Comput.-Aided Mol. Des.* **1997**, *11*, 425–445.
- (102) Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A Program to Check the Stereochemical Quality of Protein Structures. *J. Appl. Crystallogr.* **1993**, *26*, 283–291.
- (103) Roth, B. L.; Palvimäki, E. P.; Berry, S.; Khan, N.; Sachs, N.; Uluer, A.; Choudhary, M. S. 5-Hydroxytryptamine_{2A} (5-HT_{2A}) Receptor Desensitization Can Occur Without Down-Regulation. *J. Pharmacol. Exp. Ther.* **1995**, *275*, 1638–1646.
- (104) Choudhary, M. S.; Sachs, N.; Uluer, A.; Glennon, R. A.; Westkaemper, R. B.; Roth, B. L. Differential Ergopeptide Binding to 5-Hydroxytryptamine_{2A} Receptors: Ergolines Require an Aromatic Residue at Position 340 for High Affinity Binding. *Mol. Pharmacol.* **1995**, *47*, 450–457.
- (105) Wang, C. D.; Gallaher, T. K.; Shih, J. C. Site-directed Mutagenesis of the Serotonin 5-Hydroxytryptamine₂ Receptor: Identification of Amino Acids Necessary for Ligand Binding and Receptor Activation. *Mol. Pharmacol.* **1993**, *43*, 931–40.
- (106) Choudhary, M. S.; Craig, S.; Roth, B. L. A Single Point Mutation (Phe³⁴⁰→Leu³⁴⁰) of a Conserved Phenylalanine Abolishes 1-[¹²⁵I]iodo-(2,5-dimethoxy)phenylisopropylamine and [³H]Mesulergine but not [³H]Ketanserin Binding to 5-Hydroxytryptamine₂ Receptors. *Mol. Pharmacol.* **1993**, *43*, 755–761.
- (107) Roth, B. L.; Choudhary, M. S.; Craig, S. Mutagenesis of 5-HT₂ Serotonin Receptors: What Does an Analysis of Many Mutant Receptors Tell Us. *Med. Chem. Res.* **1993**, *3*, 297–305.
- (108) Kristiansen, K.; Kroeze, W. K.; Willins, D. L.; Gelber, E. I.; Savage, J. E. A Highly Conserved Aspartic Acid (Asp 155) Anchors the Terminal Amine Moiety of Tryptamines and is Involved in Membrane Targeting of the 5-HT_{2A} Serotonin Receptor but Does Not Participate in Activation via a “Salt-Bridge Disruption” Mechanism. *J. Pharmacol. Exp. Ther.* **2000**, *293*, 735–746.
- (109) Almula, N.; Ebersole, B. J.; Ballesteros, J. A.; Weinstein, H.; Sealfon, S. C. Contribution of a Helix 5 Locus to Selectivity of Hallucinogenic and Nonhallucinogenic Ligands for the Human 5-Hydroxytryptamine_{2A} and 5-Hydroxytryptamine_{2C} Receptors: Direct and Indirect Effects on Ligand Affinity Mediated by the Same Locus. *Mol. Pharmacol.* **1996**, *50*, 34–42.
- (110) Ballesteros, J. A.; Weinstein, H. Integrated Methods for the Construction of Three Dimensional Models and Computational Probing of Structure–Function Relationships in G-Protein Coupled Receptors. *Methods Neurosci.* **1995**, *25*, 366–428.
- (111) Barton, G. J. ALSCRIPT: A Tool to Format Multiple Sequence Alignments. *Protein Eng.* **1993**, *6*, 37–40.

JM800771X